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ABSTRACT 
 
 Survival, mortality, morbidity, complication rate, symptom recurrence and need for re-
interventions have long been used as benchmarks of cardiac surgery. These variables are easily and 
reliably construed, they are easy to iterate, and they are comparable regardless of the patients’ 
cultural, social, or educational background. The current trend, however, is also to assess the patients’ 
subjective health-related quality of life (HRQoL), especially among the elderly and more morbid 
patients. The evaluation of the benefits of cardiac surgery should be a comprehensive integration of 
both objective and subjective outcome measures. 
 This study is based on a comprehensive outcome analysis of 604 cardiac operated patients at the 
Kuopio University Hospital during 1990 and 2007. It examines several clinically relevant factors 
contributing to objective and subjective outcome measures. The study consists of four papers (I-IV). 
The specific objectives were to assess the long-term effects of postoperative conduction 
abnormalities on survival after primary coronary artery bypass grafting (I), to analyze the differences 
between mitral valve plasty and mitral valve replacement on survival and HRQoL (II), to investigate 
the long-term benefits of cardiac surgery on survival and HRQoL of octogenarians (III), and to study 
the implications of pacemaker-requiring conduction abnormalities after tricuspid valve surgery and to 
assess its impact on long-term survival, mortality, morbidity, and HRQoL (IV). 
 The findings suggest: firstly, survival of the coronary artery bypass grafted patients is 
comparable to an age- and sex-matched reference population. However, coronary artery bypass-
related permanent conduction abnormalities are associated with prolonged hospitalization, but they 
do not contribute to increased cardiac mortality during long-term follow-up (I). 
 Secondly, survival is longer after mitral valve plasty than after mitral valve replacement. 
However, the HRQoL of patients who have undergone mitral valve plasty is similar to the HRQoL 
after mitral valve replacement. In terms of the variables related to HRQoL, mitral valve operated 
patients do not differ markedly from the age- and sex-matched reference population (II). 
 Thirdly, the long-term HRQoL and survival of the patients who have undergone cardiac surgery 
at the age of 70 years are comparable to the age- and sex-matched reference population. The 
HRQoL does deteriorate after cardiac surgery, and this takes mainly place in the physical domains of 
HRQoL (III). 
 Fourthly, the need for a permanent pacemaker after tricuspid valve surgery is high, and 
permanent pacemakers are needed throughout the long-term follow-up. Also, the life expectancy of 
patients with a permanent pacemaker after tricuspid valve surgery is longer than of patients with no 
pacemaker. On the other hand, patients with a pacemaker had more thromboembolic complications 
and impaired HRQoL in the physical domains (IV). 
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1. INTRODUCTION 
 Attempts to temporarily substitute a patient’s heart and lungs with a mechanical device were 
originally made in 1812, when Julien Jean César LeGallois first presented the idea of artificial 
circulation (Griffenhagen and Hughes 1955). Since then, the history of the development of 
cardiopulmonary bypass (CPB) includes the first design of a CPB device by von Frey and 
Gruber in 1885 (von Frey and Gruber 1885) and the proposal in 1935 by Alexis Carrel and 
Charles Lindbergh (Carrel and Lindbergh 1935).  
 The modern era in cardiac surgery began in 1953, when John Gibbon reported the first 
successful use of extracorporeal circulation by means of an oxygenator (Gibbon 1954). The first 
successful coronary artery bypass grafting (CABG) was performed in 1964 by Vasilii Kolesov 
who grafted the left internal mammary artery (LITA) to the left anterior descending artery 
(LAD) without CPB (Kolesov 1965). Three years later René Favaloro began to use routinely the 
reversed greater saphenous vein for aortocoronary grafting (Favaloro 1969). The era of valve 
surgery started in 1948, when Dwight Harken performed the first closed mitral commissurotomy 
to relieve severe rheumatic mitral stenosis (Harken et al. 1948). In 1952, Charles Hufnagel 
implanted for the first time a prosthetic valve in the descending aorta (Hufnagel 1954), and in 
1960, Nina Starr Braunwald successfully replaced a mitral valve in patient who lived about 
three months (Braunwald 1960). 
 Now the surgical treatment of various cardiac conditions, e.g., coronary artery disease 
(CAD), valve disorders, combination of these, and complex congenital heart diseases, is 
possible. Surgical treatment of adult cardiac diseases has become routine only during the past 
three decades - despite the fact that the feasibility of open heart surgery was shown already in 
the mid-1900s. There are a number of factors that have contributed to the improved outcomes of 
adult cardiac surgery patients, including the development of surgical technique as such, 
refinement of myocardial preservation and CPB, introduction of better pharmacological agents, 
and a more comprehensive understanding of the natural history of cardiac diseases. These allow 
more appropriate timing of interventions, and provide more accurate predictive models of 
operative risk and more optimal patient selection. As a result, the mortality of most cardiac 
operations of adults has dwindled – despite the fact that many high-risk patients undergo 
surgery. In the earlier decades, the benefit of open heart surgery was measured in terms of 
extended lifetime. Now, when cardiac operations are increasingly performed on elderly patients, 
the impact of cardiac intervention on subjectively experienced health-related quality of life 
(HRQoL) will perhaps be more important than its effect on longevity alone. Under these 
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circumstances, the survival variable no longer reflects the primary intention of treatment of 
cardiac surgery, although the outcome must also be evaluated in a more comprehensive context, 
including the impact of cardiac surgery on patient’s self-perceived HRQoL. 
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2. REVIEW OF THE LITERATURE 
2.1. Scope and importance of cardiac and cardiovascular conditions 
 Despite the fact that mortality from cardiovascular diseases has significantly decreased over 
the last decades, they are still the main reason for death and account for more than 40% of all 
deaths in Finland. In 2007, altogether 20,312 (383/100,000) deaths in Finland were due to 
cardiovascular diseases (Tilastokeskus 2009a), and CAD caused about one out of every four 
deaths (219/100,000) in Finland. 
 Treatment for CAD was needed in 2004 by 59,159 patients. This was equivalent to 75,964 
hospital admission due to angina pectoris and 13,771 due to myocardial infarction. This caused 
a huge load to the Finnish healthcare system: there were 77,495 hospitalization periods and 
660,085 patient hospital days. In 2008 the number of CABGs amounted to 4,017, the number of 
percutaneous coronary interventions to 8,597, and the number of coronary angiographies to 
22,913 due to CAD (Suomen Kardiologinen Seura 2009). 
 According to the American Heart Association (AHA) in 2005 the overall mortality rate from 
cardiovascular diseases in United States was 279/100,000. CAD caused about one out of every 
five deaths in the United States, and CAD-related mortality in 2005 was 445,687 (148/100,000) 
patients (Lloyd-Jones et al. 2009). In 2009, 785,000 Americans will have a new myocardial 
infarction, and about 470,000 will have a recurrent infarction.  
 The overall total-mention mortality rate from valvular heart disease was 43,900. This is the 
number of death certificates in a year that mention the given disease classification either as the 
underlying cause or as a contributing cause. According to subgroup classification, the total-
mention mortality from aortic valve disorder was 27,390 patients, from mitral valve disorder 
6,210 patients, and from tricuspid valve disorder 114 patients. Arrhythmias were the reason of 
total-mention mortality of 466,750 patients (Lloyd-Jones et al. 2009). 
 
2.2. Survival and mortality after cardiac surgery 
 The survival benefit acquired from cardiac surgery has steadily increased over the years 
despite the fact that there has been a marked increase in the average age of the cardiac surgical 
population over the last ten years. The average age of patients referred for cardiac surgery has 
increased from 58 to 64 years over the last decade – an average increase in age of one year for 
every two years (National Adult Cardiac Surgical Database Report 2000-2001). It is worth 
noting, however, that the survival benefits of cardiac surgery become evident only after long-
term follow-up.  
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2.2.1. Postoperative conduction defects and survival 
 The impact of permanent postoperative conduction defects (CD) after cardiac surgery on 
mortality and morbidity has become less marked over the years since surgery-related CD is 
encountered more rarely. The recent study by Cook and colleagues reported a marked decrease 
in the incidence of new onset CD in CABG patients between 1991 and 2001. The early 
postoperative incidence of new CDs in 2001 was approximately one third of that of 1991 (19% 
vs. 6%, respectively). Also, 9% of the patients had a CD at the time of discharge in 1991, 
whereas the corresponding figure in 2001 was 7% (Cook et al. 2005). However, there is some 
evidence that a new, permanent CD after cardiac surgery may contribute negatively to long-term 
survival. Zeldis and co-workers reported that 20% of patients with a new left-sided CD died 
during the one to three years follow-up compared with only 7% of patients without a new 
permanent postoperative CD (Zeldis et al. 1978). Bateman and colleagues found in their series 
of 227 consecutive CABG-patients that among patients with preoperative or CABG-related left 
bundle branch block (LBBB) or intraventricular CD the mortality risk was no less than 38% 
during 5-years of follow-up compared to patients with right-sided or no CD whose risk was only 
6%. Most of the deaths occurred during the first year after operation. The authors concluded that 
CD probably relates to cardiac mechanical dysfunction or ventricular arrhythmias and this poses 
initially a high risk for patients (Bateman et al. 1985). However, some reports from the same era 
have found no relation between CDs and survival. Wexelman and colleagues investigated 200 
consecutive CABG-patients without a preoperative CD; 45 patients developed a new CD after 
CABG and 155 patients did not. The groups were relatively well-matched in terms of 
preoperative characteristics. As a result, the authors did not find any survival difference between 
the CD+ and CD- groups at 14 months follow-up regardless the type of CD, and concluded that 
the a new CD does not affect prognosis (Wexelman et al. 1986). Similar results were reported 
by Chu and co-workers in a series of 913 CABG-patients 17% of whom developed transient CD 
(resolved before discharge) and 14% permanent CD (until discharge). They reported that a new 
perioperative CD, including isolated new LBBB, did not impair the survival rate of patients who 
were followed for up to three years after surgery (Chu et al. 1987).   
 
2.2.2. Survival of octogenarians after cardiac surgery 
 In a prospective study by Avery and co-workers of 104 cardiac operated octogenarians, the 
30-day mortality was 13.5% as compared with 3.4% among 351 reference patients aged 65-75 
years (Avery et al. 2001). Similarly, Chee and co-workers compared 2,272 patients over 75 
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years with 9,745 patients below 75 years and found, not surprisingly, that older age was 
associated with higher mortality rates during the in-hospital period and short-term follow-up. 
They reported a 3.4-fold (4.1% vs. 1.2%) increase in in-hospital mortality in patients >75 years 
compared to the younger age group (Chee et al. 2004). The long-term survival rates after 
isolated CABG of patients older than 75 years has increased in the United States from 92% in 
1998 to 94% in 2001 (National Adult Cardiac Surgical Database Report 2000-2001). An 
analysis of Petersen and colleagues of 24,461 octogenarians who underwent CABG between 
1987 and 1990 showed that the life span of the survivors was similar to that of the general 
population (Petersen 1995). Similarly, Ishikawa and associates found in 237 cardiac operated 
octogenarians that the early mortality rate was 9%, but that the 5-year actuarial survival rate of 
the hospital survivors was 75%. There were no significant differences in survival among CABG, 
valve or combination procedures. Although a marked increase in morbidity and mortality was 
noted among patients with urgent and emergent needs, the risk-benefit profile was considered 
acceptable (Ishikawa 2004). Improved surgical techniques have decreased operative mortality. 
Ivanov and colleagues reported a 34% reduction in the adjusted operative mortality risk among 
3,330 consecutive patients aged 70 years and older who underwent isolated CABG between 
1982 and 1996 (Ivanov et al. 1998). 
 
2.2.3. Survival after mitral valve surgery 
 Studies on survival after mitral operations have shown that mitral valve plasty (MVP) is 
superior to mitral valve replacement (MVR). However, it is crucial to note that the etiology of 
mitral valve disease is decisive for selection of technique and patient outcome. In general, 
patients with degenerative mitral valve disease are most suitable for reconstructive surgery, and 
long-term results of repair are excellent in this group compared to the outcome of patients with 
rheumatic mitral valve disease, where repair is more difficult and less durable. In these selected 
cases, MVR may be the only feasible option for reconstruction of the diseased mitral valve 
apparatus. It is practically impossible, at least in valve surgery, to design prospective 
randomized clinical trials, since operative techniques cannot be selected randomly. Thus, the 
results regarding outcomes after mitral valve surgery are primarily based on non-randomized, 
register-based materials. The study reports are very heterogeneous regarding co-morbidities and 
etiologies of mitral disease.   
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 MVP is currently applied to close to 60% of all patients who require surgery for mitral valve 
disease in the United States (Ad et al. 2008). In terms of operative and early (within 30 days) 
mortality, MVP seems to be superior to MVR. Akins and co-workers reported lower hospital 
mortality in patients who underwent MVP (3%) compared to patients who underwent MVR 
(12%; Akins et al. 1997). These results are corroborated by Enriquez-Sarano and Gogbashian, 
who found that operative mortality in 195 MVP patients was 2.6%, compared with 10.3% in 
214 MVR patients who were operated due to organic mitral regurgitation (Enriquez-Sarano et 
al. 1995). Similarly, the in-hospital mortality among 218 MVP and 74 MVR patients who were 
operated on for degenerative mitral valve disease was 0.7% and 13.9%, respectively 
(Gogbashian et al. 2006). However, the long-term survival of the patients who had undergone 
concomitant CABG did not differ between these two groups (Gogbashian et al. 2006). The 
report by Mihaljevic and associates regarding 390 patients who had undergone CABG with 
(n=290) or without (n=100) MVP concluded by stating that although CABG in combination 
with MVP reduces postoperative mitral regurgitation and improves early symptoms compared 
with CABG alone, it does not improve the long-term functional status or survival of patients 
with severe functional ischemic mitral regurgitation (Mihaljevic et al. 2007).   
 Enriquez-Sarano and associates reported higher 10-year survival rates after MVP compared 
to MVR performed due to organic mitral regurgitation – 68% versus 52% (Enriquez-Sarano et 
al. 1995). Gillinov and colleagues studied a cohort of 482 patients who required surgery for 
ischemic mitral regurgitation and underwent either MVP or MVR and found that in combination 
with CAD, late survival was relatively poor. Overall, however, most patients with ischemic 
mitral regurgitation benefit from MVP compared to MVR in terms of survival. The 1- and 5-
year survival rates were 82% and 58% compared with 56% and 36%, respectively. In the most 
complex, high-risk settings, survival after MVP and MVR were similar (Gillinov et al. 2001). In 
contrast, a more recent study of Gillinov and colleagues revealed that the 5-, 10-, and 15-year 
survival of 3,286 patients who had undergone either MVP or MVR due to isolated degenerative 
mitral valve disease (without CAD) was 95%, 87%, and 68% in MVP group, versus 80%, 60%, 
and 44% in MVR group. When the patients were propensity matched, the survival between the 
MVP and MVR groups was, unexpectedly, similar: 86%, 63%, and 43%, versus 83%, 62%, and 
48%, respectively (Gillinov et al. 2008). 
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2.2.4. Survival after tricuspid valve surgery 
 Tricuspid regurgitation (TR) is a common echocardiographic finding that is present in 80% 
to 90% even of healthy individuals (Singh et al. 1999). The survival outcome is unambiguously 
related to the severity of TR. Nath and associates reviewed retrospectively the data of 5,223 
patients who had undergone echocardiography over a period of four years in Veterans Affairs 
Medical Centers. They found that the prognosis was strictly dependent on the grade of TR. The 
1-year survival of patients with severe, moderate, mild, and no TR was 64%, 79%, 90%, and 
92%, respectively. The authors concluded that the severity of TR was associated with worse 
survival regardless of left ventricular ejection fraction or pulmonary artery pressure. In addition, 
severe TR was associated with a poor prognosis independent of age, biventricular systolic 
function, right ventricular size, and dilatation of the inferior vena cava (Nath et al. 2004). There 
is, regrettably, a paucity of survival data on patients who have undergone tricuspid valve (TV) 
surgery. The survival outcome after TV surgery is undoubtedly related to underlying cardiac 
disease and it might be related to the surgical technique. Ishan and colleagues reported 10- and 
15-years survival rates of 37% and 30%, respectively, among 42 patients who underwent 
tricuspid valve replacement (TVR) for rheumatic disease (64%), Ebstein’s anomaly (31%) or 
endocarditis (5%). They found that an elevated pulmonary artery pressure and a rheumatic 
etiology affected the long-term results unfavorably (Ishan et al. 2007). Ratnatunga and co-
workers reported no survival difference between patients who had received a biological or a 
mechanical tricuspid valve: the 1-, 5-, and 10-year survival rates were 71%, 62%, and 48% for 
biological- and 74%, 58%, and 34% for mechanical prostheses, respectively (Ratnatunga et al. 
1998). 
 There is some evidence that tricuspid valve plasty (TVP) may have some advantages over 
TVR – when feasible – in terms of survival. Guenther and associates reported that the survival 
among 416 patients ten years after TVP was 48% and after TVR 37 % (Guenther et al. 2008). 
McCarthy and colleagues reported an 8-year survival of 50% among 790 patients who 
underwent TVP (McCarthy et al. 2004).  
 
2.3. Risk calculations and risk factors for mortality 
 Comprehensive mortality risk factor analysis after cardiac surgery based on individual 
studies is challenging. Study populations are heterogeneous, clinical practices and surgical 
techniques vary, follow-up periods are variable, and, ultimately, there are mixed results and 
conclusions drawn from the individual studies. This explains why predicting the outcome and 
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risk of single patients is practically impossible. The most feasible approach to assess the risk of 
operative mortality of cardiac surgery is to use validated risk scores calculators based on the 
large patient cohorts. The most common scoring systems are the European EuroSCORE, i.e., the 
European System for Cardiac Operative Risk Evaluation (Nashef et al. 1999 and 2002, Roques 
et al. 1999 and 2003, Pitkänen et al. 2000, EuroSCORE 2009) and the American STS risk 
calculator (Shroyer et al. 2003, STS 2009). EuroSCORE is based on risk factor analysis of 
19,030 consecutive patients from 128 hospitals in eight European countries (Roques 1999), and 
the STS risk calculator refers to the Society of Thoracic Surgeons’ National Cardiac Database 
(STS NCD; Shroyer et al. 2003, STS 2009). Both scoring systems predict the risk of operative 
mortality and morbidity related to cardiac surgery of adult patients based on patient 
demographics and a number of clinical variables. Although both systems have been shown to be 
a powerful and highly discriminatory risk predictor, there is evidence that as cardiac surgical 
outcomes have improved, both scoring systems tend to overestimate the actual risk (Ferguson et 
al. 2002, Karabulut et al. 2003, Osswald et al. 2009). This is especially true for valve surgery 
and high risk patients (Karabulut et al. 2003, Osswald et al. 2009), although EuroSCORE has 
also shown to be useful predictor of immediate and late outcome after mitral valve surgery 
(Heikkinen et al. 2007). However, more recent data suggest that STS risk calculator is more 
reliable in these situations than the EuroSCORE (Dewey et al. 2008). Van Gameren and 
associates have suggested that it might be reasonable to separate the risk stratification models 
for heart valve surgery and coronary artery surgery or a combination of these (van Gameren 
2008). 
 In 2009, the STS working group (STS Quality Measurement Task Force) published three 
separate papers on the risk factors for mortality of patients who had undergone either CABG, 
isolated valve surgery or combined valve surgery and CABG (O’Brien et al. 2009, Shahian et al. 
2009a, Shahian et al 2009b). These reports are based on cumulative information in the STS 
database that includes 774,881 isolated CABG patients, 67,292 isolated aortic valve 
replacement (AVR) patients, 21,229 isolated MVR patients, 21,238 isolated MVP patients, and 
101,661 CABG and/or AVR and/or MVR or MVP patients. A summary of the relevant odds 
ratios and their 95% confidence intervals is shown in Table 1.   
 
2.4. Incidence and morbidity risk factors  
 Cardiac surgery-related morbidity is closely associated to the patient’s underlying medical 
condition. Stamou and associates reviewed 2,221 patients who had undergone either isolated 
25 
 
  
CABG, valve surgery or a combination of these. The postoperative morbidity figures for stroke 
was 2%, sepsis 3%, renal failure 7%, atrial fibrillation 29%, hemodialysis 2%, hemorrhage-
related re-exploration 6%, blood transfusion 40%, cardiac tamponade 1%, mediastinitis 1%, re-
admission to intensive care unit 8%, prolonged stay in hospital over nine days 22%, and 
prolonged intubation over 24 hours 11% (Stamou et al. 2008). Ruel and colleagues found in a 
study of 3,189 patients that approximately 20% of all patients with valve prostheses experience 
an embolic stroke within 15 years after valve replacement. Significant risk factors for late 
embolic stroke were female sex, age older than 75 years, left ventricular dysfunction, history of 
smoking or current smoking, and mechanical mitral prosthesis (Ruel et al. 2004). 
 In 2009, the STS working group (STS Quality Measurement Task Force) published three 
papers from the same patient cohorts and reported the risk factors for morbidity among patients 
who had undergone either CABG, isolated valve surgery or combined valve surgery and CABG 
(O’Brien et al. 2009, Shahian et al. 2009a, Shahian et al. 2009b). There were eight endpoints:  
cerebrovascular accident or stroke, renal failure, prolonged ventilation, deep sternal wound 
infection, reoperation, composite adverse outcome, prolonged duration of stay, and short 
duration of stay. Tables 2 and 3 show the odds ratios for morbidity outcomes related to 
cerebrovascular, renal, pulmonary, and infection endpoints, reoperations, and prolonged 
duration of stay after isolated CABG, isolated valve or combination procedures. 
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2.5. HRQoL after cardiac surgery 
 In 1948, The World Health Organization (WHO) defined health as being not only the 
absence of disease and infirmity but also the presence of physical, mental, and social well-being 
(Constitution of the World Health Organization 1952). The term quality of life (QoL) and, more 
specifically, health-related quality of life (HRQoL) refers to physical, psychological, and social 
domains of health, seen as distinct domains that are influenced by a person’s experience, beliefs, 
expectations, and perceptions (Brook et al. 1983, Testa and Simonson 1996). For clarity, the 
term HRQoL has been used through this study. An assessment of HRQoL has become 
increasingly important, both as a measure of risk assessment and as an outcome. Also, beyond 
subjective perception of the HRQoL, the impact of surgical intervention on HRQoL has become 
more relevant in today’s health care practice where monetary measures do not readily apply. 
The growing fields of outcome research and health-technology assessment evaluate the efficacy, 
cost effectiveness, and net benefit of new therapeutic strategies to determine whether the 
associated increases in expenditures for health care are justified (Thier 1992, Taskinen et al. 
2008). 
 Tools available for assessment of HRQoL require a shift in thinking from only exact 
mortality, morbidity, and survival figures to probabilities. In general, reports after cardiac 
surgical interventions show that HRQoL has improved or is at least equal to the matched 
reference population for most cardiac surgical patients (Sjöland et al. 1999, Rumsfeld et al. 
2001, Järvinen et al. 2003, Maliwa et al. 2003, Welke et al. 2003, Koch et al. 2007). The 
greatest improvement in HRQoL occurs probably in patients with the worst preoperative, 
cardiac-symptoms related HRQoL, whereas patients with a relatively good HRQoL benefit little 
(Rumsfeld et al. 2001). Several investigators have reported that markedly impaired HRQoL 
preoperatively is associated with higher mortality (Rumsfeld et al. 1999, Curtis et al. 2002, 
Koch et al. 2007). Rumsfeld and co-workers reported that among 2,480 patients who underwent 
CABG the physical component of the SF-36 score was an independent risk factor for six 
months mortality. The risk for mortality was 1.39 times higher in patients who had a 10-point 
lower preoperative score in the physical well-being domain compared to patients with a normal 
value. In contrast, the baseline mental component summary score did not predict mortality 
(Rumsfeld et al. 1999). Similar findings were published by Ho and colleagues, who found that 
the preoperative physical and mental health status were independent predictors of mortality 
after cardiac surgery in patients 65 years or older but not in younger patients. A score 10 points 
below the healthy average in the domains of physical and mental well-being at baseline 
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increased the relative risk of postoperative mortality by 51% and 28%, respectively (Ho et al. 
2005). Koch and associates examined the survival of 6,305 patients who underwent either 
CABG or a valve procedure or a combination of these. They found that a poor HRQoL after 
recovery from cardiac surgery identifies patients who are at risk for reduced long-term survival 
(Koch et al. 2007). Similarly, Curtis and colleagues reported that poor preoperative HRQoL is 
related to increased in-hospital mortality and prolonged hospital stay after CABG (Curtis et al. 
2002). On the other hand, prolonged stay in intensive care unit over eight days after primary 
heart valve surgery has been associated with reduced HRQoL in terms of physical and mental 
health still five years after surgery (Hellgren and Ståhle 2005). 
 The impact of cardiac surgical techniques on HRQoL can be studied if there are two or more 
technical options to treat a certain heart condition. Two recent articles reported that MVP might 
be better than MVR in terms of HRQoL (Goldsmith et al. 2001, Sedrakyan et al. 2006). Immer 
and co-workers were not able to corroborate this finding in their study of 115 consecutive mitral 
valve patients; they found that the mid-term outcome in terms of survival and HRQoL was 
similar in the two groups (Immer et al. 2003). However, the HRQoL among long-term survivors 
after MVP have shown to be comparable to that of an age- and sex-matched general population. 
Heikkinen and colleagues investigated the HRQoL of 109 patients who had undergone MVP 
due to degenerative or ischemic mitral valve regurgitation, and found no significant differences 
in terms of HRQoL between MVP-operated patients and an age- and sex-adjusted Finnish 
general population (Heikkinen et al. 2005a).  
 Identification and assessment of the predictors that contribute to the patient’s postoperative 
HRQoL would be most useful for preoperative patient counseling and even patient selection. 
The anticipated HRQoL after surgery can provide valuable information for discharge planning 
(Elliot et al. 2006) and rehabilitation (Engblom et al. 1992, 1994 and 1997). A number of 
investigators have reported several circumstances that predict the postoperative HRQoL. 
Rumsfeld and colleagues analyzed risk factors related to impaired HRQoL after CABG among 
1,973 male patients six months after operation. Factors that predicted a low postoperative score 
for the physical dimensions were: peripheral vascular disease, chronic obstructive pulmonary 
disease, hypertension, smoking, low left ventricular ejection fraction, and a history of 
neurological disease (Rumsfeld et al. 2004). Welke and associates identified diabetes, chronic 
obstructive pulmonary disease, peripheral vascular disease, obesity, and physical function at 
baseline as risk factors for impaired HRQoL after CABG (Welke 2003). In the case of mitral 
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surgery, high age, high preoperative and postoperative NYHA-class, a need for nitroglycerin 
and diuretics correlate with impaired HRQoL (Chocron et al. 1996). 
 The relation between age and HRQoL has been investigated by Järvinen et al. (2003) and 
Loponen et al. (2007). During short-term follow-up, elderly patients derived less benefit in 
terms of HRQoL from cardiac surgery than younger patients. Järvinen and co-workers studied 
508 patients who had undergone CABG and reported that patients aged >75 years had higher 
mortality and morbidity and a poorer HRQoL compared with younger patients. Age is a risk 
factor for reduced postoperative HRQoL after mitral valve surgery (Chocron et al. 1996). 
 The results regarding the association between TV surgery and HRQoL in adult cardiac 
surgery are very limited. Do and colleagues reviewed data regarding 454 patients who had 
undergone either TVR of TVP during the years 1978 and 1998. Although HRQoL was not 
specifically addressed, the authors concluded that most of the survivors after TV surgery could 
expect an improvement in their HRQoL as their NYHA-class declined (Do et al. 2000).  
 
2.6. Conduction abnormalities 
 The conduction system of the heart is susceptible to reversible and irreversible damage at the 
time of cardiac surgery. The consequences are conduction abnormalities which are categorized 
as AV-blocks, bundle branch blocks, and hemiblocks. The course of the conduction system is 
shown in Figure 1. 
 
Figure 1. Conduction system of the heart. Copyright 2009 ADAM Inc., Atlanta, Georgia, U.S. Figure is 
freely available from Medline Plus, a service of the U.S. National Library of Medicine and the National 
Institutes of Health: http://www.nlm.nih.gov/medlineplus/ency/imagepages/18052.htm 
 
 
 
 
 
 
 
 
 
 
 
32 
 
  
2.6.1. AV-blocks 
 AV-blocks are classified as first degree (1st degree), second degree (2nd degree), and third 
degree (3rd degree) AV-blocks. 
 The 1st degree AV-block is characterized by a prolonged delay in conduction at the AV-node 
or bundle of His. Corresponding ECG finding is a PR interval longer than 200 ms. In 1st degree 
AV-block every atrial impulse passes through the AV-node to the ventricles, and therefore, 1st 
degree AV-block is rather a delay than an actual block in the conduction system.  
 In 2nd degree AV-block, all atrial impulses do not pass through the AV-node resulting in 
more P waves than QRS complexes on the ECG. 2nd degree AV-blocks are subdivided into 
Mobitz I (Wenckebach block) and Mobitz II blocks. In Mobitz I the AV delay increases 
successively until one atrial impulse fails to reach the ventricle. A progressive lengthening of 
the PR-interval is seen on the ECG until a QRS complex is dropped. In Mobitz I, the AV-block 
usually resides in the AV-node. In the Mobitz II block, occasional atrial impulses are not 
conducted to the ventricles and there is no preceding progressive lengthening of the PR-interval. 
In Mobitz II, the block is usually located below the AV-node at the level of His-Purkinje 
system. A Mobitz I block can be a normal finding in healthy subjects caused by a high vagal 
tone, while the Mobitz II block is not dependent on autonomic tone and is usually considered to 
be pathological.   
 In 3rd degree AV-block (complete heart block) the atrial impulses are not conducted to the 
ventricles at all. The site of the block can be either at the level of AV-node or further down at 
the level of the His bundle. The lack of impulses from the atria leads to a ventricular escape 
rhythm that usually is 30-45 beats / minute. 
 
2.6.2. Bundle branch blocks 
 Bundle branch blocks refer to abnormal conduction in either the left or right bundle branches 
(LBBB or RBBB) distal to the bundle of His. Both LBBB and RBBB cause typical findings in 
the ECG. In LBBB, left ventricular depolarization is delayed which results in wide QRS 
complexes (duration over 120 ms). Similarly, in RBBB, delay in right ventricle depolarization 
widens the QRS complex beyond 120 ms and, it too, has an easily identifiable form. 
 
2.6.3. Hemiblocks 
 Hemiblock refers to a conduction block of one of the three separate fascicles of the left 
bundle branch. A block in the septal fascicle has little clinical relevance, whereas blocks in left 
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anterior (LAHB) and left posterior (LPHB) fascicles are clinically more important. The 
diagnosis of the hemiblocks is based on left or right deviation of the frontal QRS axis in 
combination with minor criteria.  
 
2.7. Pacemaker therapy 
 The symptoms caused by conduction abnormalities (or bradycardia) after cardiac surgery are 
generally due low cardiac output or a transient loss of cerebral perfusion. The manifestations 
include fatigue, dyspnea, low exercise tolerance, dizziness, pulmonary congestion, presyncope, 
or syncope. The indications for implantation of a PM in adults have been published by the Task 
Force of the American College of Cardiology and American Heart Association (Gregoratos et 
al. 2002ab) and the Task Force of the European Society of Cardiology and the European Heart 
Rhythm Association in 2007 (Vardas et al. 2007). After cardiac surgery, the indications for PM 
are usually 3rd degree AV-block, symptomatic or significant sinus node dysfunction, slow 
ventricular rate during atrial fibrillation, tachycardia-bradycardia syndrome (fast atrial 
fibrillation alternating with slow sinus rhythm), and advanced 2nd degree AV-block with a slow 
ventricular response. The optimal time of implantation of a PM is difficult to determine because 
occasionally the need is transient. Since implantation of a PM carries a low complication rate, 
the greatest benefit of a PM is achieved if it is implanted about 4-5 days after surgery (Glikson 
et al. 1997). 
  
2.8. Need for PM after cardiac surgery 
 A temporary need for pacing is very common immediately after cardiac surgery. Most 
patients with normal sinus rhythm before the operation will regain it within a few days after the 
operation (Glikson et al. 1997, Gordon et al. 1998). 
 The proportion of patients needing a PM after cardiac surgery ranges reportedly from 0.4% 
to as high as 28%. The incidence is related to the type of surgery; it is below 1% after CABG 
and 3%-6% after valve surgery (Gordon et al. 1998, Koplan et al. 2003, Limongelli et al. 2003, 
Dawkins et al. 2008, Onalan et al. 2008). Several studies have sought predictive factors for PM 
after cardiac surgery, and found that TV surgery unequivocally carries the highest risk for PM 
implantation compared with coronary, aortic, mitral, or multiple valve surgery (Koplan et al. 
2003). Other predictors for PM include preoperative conduction abnormalities, re-operative 
surgery, type of cardioplegia, renal failure, endocarditis, prolonged aortic cross-clamp time, 
electrolyte imbalance, high age, female sex, previous MIs, left main coronary artery stenosis, 
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long-standing hypertension, preoperative digitalis treatment, and low myocardial temperature 
during surgery (Baerman et al. 1987, Caspi et al. 1987, Caretta et al. 1991, Salerno et al. 1991, 
Mustonen et al. 1995, Dawkins et al. 2008, Onalan et al. 2008). 
 Koplan and co-workers developed and validated a risk score calculator to predict the need 
for PM after valve surgery (Koplan et al. 2003). In their comprehensive series of 4,694 patients, 
they found that preoperative RBBB or LBBB, multivalve surgery (especially when including 
TV surgery), preoperative PR-interval >200 ms, prior valve surgery, and age over 70 years were 
the strongest independent predictors for the need of PM. 
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3. OBJECTIVES OF THE PRESENT STUDY 
The purpose of this study was to do a comprehensive analysis of patient outcomes after cardiac 
surgery with regard to survival, mortality, morbidity, and HRQoL. The specific aims were: 
 
1. To assess the effects of postoperative conduction abnormalities on long-term survival after 
primary CABG.  
 
2. To analyze the differences between MVP and MVR on survival and HRQoL and to assess 
the risk factors for mortality and impaired HRQoL. 
 
3. To investigate the long-term benefits of cardiac surgery on survival and HRQoL of 
octogenarians. 
 
4. To study the impact of PM-requiring conduction abnormalities after TV surgery on long-
term outcome in terms of survival, morbidity, and HRQoL. 
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4. PATIENTS AND METHODS 
4.1. Study setting and patient population (I-IV) 
 This study is a composition of four single center registry studies carried out at the 
Department of Surgery at the Kuopio University Hospital. The study was approved by the 
Ethics Committee of the Kuopio University Hospital and written informed consent was obtained 
from all patients. 
 The departments of Surgery and Anesthesiology at the Kuopio University Hospital have 
since 1992 maintained prospectively a register of patients referred for cardiac surgery. This 
database includes comprehensive clinical data of all cardiac surgical patients operated at the 
Kuopio University Hospital in terms of demographics, underlying or contributing cardiac 
conditions, co-morbidities, and medication. In addition, factors related to cardiac surgery and 
perioperative or postoperative complications until discharge from the hospital have been 
recorded. To verify long-term survival and authentic causes of deaths, all patients were traced 
with respect to mortality data from the continuously updated National Cause of Death Register 
during the closing intervals of each study. The HRQoL was investigated cross-sectionally in 
Studies II and IV, and longitudinally in Study III by using the Nottingham Health Profile 
(NHP) HRQoL questionnaire. Comparisons regarding HRQoL were made between the 
appropriate study groups and age- and sex-matched Finnish reference population. Altogether 
604 patients were included in this study. 
 
I. The first patient cohort consisted of 180 consecutive, electively operated patients who 
underwent isolated CABG between June 1990 and March 1991, 63 of whom (35%) developed a 
new permanent CD during the CABG. Patients who underwent emergency operation or re-
operation, and patients with any CD confirmed by preoperative ECG analysis were excluded. 
 
II. The second patient cohort consisted of 184 consecutive patients who underwent primary 
MVP (n=85) or MVR (n=99) for mitral regurgitation between January 1992 and December 
1996. Of these, 113 (61%) underwent concomitantly CABG (72% in the MVP group, and 53% 
in the MVR group, respectively). Exclusion criteria were mitral stenosis, aortic or tricuspid 
valve surgery, previous valve repair or replacement, or congenital heart disease. 
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III. The third patient cohort consisted of 104 consecutive patients who were older than 70 years 
at the time of primary cardiac surgery in 1993. Of these, 60 patients (58%) underwent CABG, 
12 patients (11%) valve surgery, and 32 patients (31%) combined CABG and a valve procedure. 
 
IV. The fourth patient cohort consisted of 136 consecutive patients who underwent either TVP 
or TVR between January 1992 and September 2007. Twenty-five patients (18%) had only TV 
surgery, 91 patients (67%) had double valve surgery, and 20 patients (15%) had triple valve 
surgery. CABG was performed concomitantly in 37 (27%) cases. 
 
Patient data of Studies I, II, III, and IV are summarized in Table 4. 
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Table 4. Demographic and clinical data of patients (Studies I, II, III, and IV). 
 
Characteristic Study I (n=180) Study II (n=184) Study III (n=104) Study IV (n=136) 
 
Sex 
 male  148 (82)  126 (68)   50 (48)  54 (40)  
 female  32 (18)  58 (32)   54 (52)  82 (60)  
Age at operation (years)  55.7 ± 8.6  61.8 ± 9.3   72.9 ± 2.9  65.0 ± 11 
BMI  (kg/m2)  -   26.4 ± 3.2   -  25.5 ± 3.7 
NYHA-class 
 I  -   1 (1)   1 (1)  1 (1)  
 II  -   42 (23)   9 (9)  22 (16)  
 III  -   91 (49)   30 (29)  89 (65)  
 IV  -   50 (27)   64 (62)  24 (18)  
Previous MI  119 (66)  60 (33)  54 (52)  15 (11) 
1 or 2-vessel disease  -   -   -  18 (13)  
3-vessel disease  -   74 (40)   80 (77)  31 (23)  
LMCAS  35 (19)  25 (14)   24 (23)  - 
Unstable angina pectoris  58 (32)  -   51 (49)  7 (5)  
Cardiac rhythm 
 sinus rhythm  180 (100)  134 (73)   -  32 (24)  
 atrial fibrillation  -   49 (26)   -  104 (76)  
 pacemaker rhythm  -   1 (1)   -  - 
Preoperative CD  
 RBBB  -   -   -  9 (7)  
 RBBB+LAHB/LPHB -   -   -  2 (1)  
 LAHB  -   -   -  5 (4)  
 LBBB  -   -   -  6 (4)  
Peripheral arterial disease -    11 (6)   6 (6)  7 (5)  
Cerebrovascular disorder -    -   11 (11)  - 
 TIA  -   6 (3)   -  7 (5)  
 stroke  -   6 (3)   -  5 (4)  
 ICB  -   -   -  2 (1)  
Severe renal failure  -   4 (2)a   26 (25)a  5 (4)b  
Diabetes  23 (13)  24 (13)   21 (20)  14 (10)  
Hyperlipidemia  -   -   39 (38)  62 (46)  
Hypertension  127 (71)  -   44 (42)  72 (53)  
Ejection fraction (%)  59 ± 11  58 ± 13   58 ± 16  54 ± 13  
Pulmonary hypertension  -   -   -  26 (19)  
Urgency of operation   
 elective  180 (100)  135 (73)   40 (39)  105 (77)  
 urgent  -   35 (19)   55 (53)  22 (16)  
 emergency  -   14 (8)   9 (9)  9 (7)  
 
 
Values denote number of patients (percentage) or mean ± standard deviation. BMI = body mass index;  CD = conduction 
defect; ICB = intracerebral bleeding; LAHB = left anterior hemiblock; LBBB = left bundle branch block; LPHB = left 
posterior hemiblock; LMCAS = left main coronary artery stenosis; MI = myocardial infarction; NYHA = New York 
Heart Association; RBBB = right bundle branch block; TIA = transient ischemic attack; aCreatinine >105 µmol/l;  
bGlomerular filtration rate <29 ml/kg/1.73m2.  
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4.2. Assessment of results of cardiac surgery 
 The outcomes after cardiac surgery may be divided into objectively measurable outcomes 
(by a clinician, researcher or statistician) and subjective outcomes (patient’s subjective 
experience of the impact of the cardiac intervention on HRQoL). 
 Objective measures, i.e., survival and mortality, morbidity, complications, symptom 
recurrence, and need for re-interventions have long been used as the criteria of success of 
cardiac surgery. These variables are easily and reliably measured, they are easy to iterate and 
they are comparable regardless of the patients’ cultural, social, or educational background. 
Albeit important, reporting only survival figures and the rate of complications are no longer the 
only acceptable benchmark in today’s practice, because modern assessment of cardiac surgery 
needs to consider both objective and subjective outcome measures comprehensively. 
 Subjective measures, i.e., patient-related outcomes, have not been the primary focus for 
clinicians, maybe because HRQoL is a subjective and abstract outcome measure and because an 
objective comparison of HRQoL as an outcome is more tricky. Nevertheless, measuring 
HRQoL is gaining importance in surgical research because there is a growing societal interest in 
HRQoL after surgical intervention. Clinicians and researchers are also interested in additional 
measures to quantify the impact of specific interventions (Spertus et al. 2002, Rumsfeld 2003).  
 
4.3. Reporting survival and mortality 
 Survival in medical research is defined as the fraction of patients living for a certain amount 
of time after a given treatment. Survival is closely associated with the underlying medical 
condition and its treatment. Actuarial and Kaplan-Meier survival analysis are two accepted 
methods to analyze survival information. An actuarial survival analysis is performed when the 
actual date of a survival event is not known. The known information is that the event has 
occurred between time tn and time tn+1. Actuarial analysis is carried out at specific time 
intervals, and the resulting graph will step only at those intervals. 
 The Kaplan-Meier method is used when the actual date of the end-point is known. End-
points not reached are treated as censored at the date of last follow-up for the analysis. The 
curves change at every event, death, or censoring (Wormuth 1999). 
 The rationale for reporting mortality figures in cardiac surgery is published in the Guidelines 
for reporting mortality and morbidity after cardiac valve intervention by Ad Hoc Liaison 
Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity (Edmunds et al. 
1996, Akins et al. 2008). The committee states that early mortality is to be reported as all-cause 
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mortality at 30, 60, or 90 days after surgery and depicted by actuarial estimates, i.e., number of 
subjects remaining at risk and confidence intervals or as percentages. All-cause mortality 
includes all deaths from any cause after cardiac surgical intervention and survival should be 
compared with an age- and sex-matched sample from the general population whenever possible. 
Cardiac mortality includes all deaths resulting from cardiac causes and is subgrouped into valve-
related deaths, sudden unexplained deaths, and deaths from other cardiac cause, e.g., from heart 
failure, acute myocardial infarction, or documented arrhythmias. A sudden unexplained death is 
one in which the cause of death has not been determined by clinical investigation or autopsy 
findings (Edmunds et al. 1996, Akins et al. 2008).  
 
4.4. Morbidity 
 According to the committee, morbidity refers to a diseased state, disability, or poor health 
due to an underlying cardiac condition, intervention, or re-intervention related to it (Edmunds et 
al. 1996, Akins et al. 2008). Morbidity in cardiac surgery is closely related to embolism or 
bleeding events due to devices, most commonly mechanical valves, used in surgery or 
unavoidable medication related to these devices or underlying cardiac condition. Device-related 
morbidity is categorized as structural valve deterioration, nonstructural dysfunction, 
thromboembolism, and valve thrombosis. Embolism is any embolic event that occurs in the 
absence of infection after the immediate perioperative period, and it can be manifested by a 
neurological event or peripheral embolic event. A neurological event includes any central, new 
neurological deficit, whether temporary or permanent and whether focal or global, that occurs 
after awakening from anesthesia. Specific neurological events include stroke, transient ischemic 
attack, clusters (multiple or repeated transient events occurring during a short period), and 
psychomotor deficit. A non-cerebral embolic event is an embolus documented operatively, at 
autopsy, or clinically that produces signs or symptoms attributable to complete or partial 
obstruction of a peripheral artery. A major bleeding event includes any episode of major internal 
or external bleeding that causes death, hospitalization, or permanent injury or that necessitates 
transfusion regardless whether the patient has or has not been taking anticoagulants or 
antiplatelet drugs. Re-intervention is any surgical or percutaneous interventional catheter 
procedure that repairs, otherwise alters or adjusts, or replaces a previous intervention (Edmunds 
et al. 1996, Akins et al. 2008). 
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4.5. Measuring HRQoL 
 Unlike standard of living, HRQoL is not a tangible thing, and so cannot be measured 
directly. Measuring HRQoL requires a valid, reproducible, and sensitive method. In the context 
of medical research, both disease-specific and generic measurement can be utilized (Kind 2001). 
 A disease-specific measure reflects the experience of a particular illness or condition or its 
treatment and is specially designed for a particular disease, patient group, or areas of function. 
The typical disease-specific measurements of patients with cardiac disease are the New York 
Heart Association classification (NYHA; The Criteria Committee of the New York Heart 
Association) and the Canadian Cardiovascular Society’s functional classification (CCS; 
Campeau 1976). The NYHA-classification categorizes heart failure patients into four groups 
based on their functional capacity (Table 5), and the CCS-classification categorizes patients into 
four groups according their severity of angina (Table 6). Other commonly used disease-specific 
measures are the Seattle Angina Questionnaire (Spertus et al. 1995), the Coronary 
Revascularization Outcome Questionnaire (Schroter et al. 2004), and the Minnesota Living with 
Heart Failure Questionnaire (Rector et al. 1987). 
 
 
Table 5. New York Heart Association’s functional classification (NYHA-classification). 
 
Class I: Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity 
does not cause undue fatigue, palpitation, dyspnea or anginal pain. 
 
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain. 
 
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. 
Less than ordinary activity causes fatigue, palpitation, dyspnea or anginal pain. 
 
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. 
Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, 
discomfort increases. 
 
 
 
 
 
42 
 
  
Table 6. Canadian Cardiovascular Society’s grading of angina pectoris (CCS-classification). 
 
Grade I: Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina with strenuous 
or rapid or prolonged exertion at work or recreation. 
 
Grade II: Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair 
climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. 
Walking more than two blocks on the level and climbing more the one flight of ordinary stairs at a normal pace and in 
normal conditions. 
 
Grade III: Marked limitation of ordinary physical activity. Walking one or two blocks on the level and climbing one 
flight of ordinary stairs in normal conditions and at normal pace. 
 
Grade IV: Inability to carry any physical activity without discomfort, angina syndrome may be present at rest. 
 
 
 Generic instruments, on the other hand, should cover a broad range of dimensions of 
HRQoL and allow comparisons between different groups of patients. An ideal generic health 
assessment would include a comprehensive measure of a person's HRQoL. The World Health 
Organization QoL group (WHOQOL Group 1993) has recommended five dimensions that 
should be included in a generic HRQoL instrument. These are physical and psychological 
health, social relationship perceptions, function, and well-being. 
 The most common instruments to assess HRQoL in medical literature related to cardiac 
surgery are the Short-Form 36 (SF-36), The Nottingham Health Profile (NHP), EQ-5D, and the 
15D (Hunt et al. 1981, Sintonen and Pekurinen 1989, Ware and Sherbourne 1992, Brooks et al. 
2003). The Finnish version of the NHP questionnaire is shown in the Appendix.  
 
4.6. Cardiopulmonary bypass 
 Cardiopulmonary bypass was performed by using a Stöckert heart-lung machine (Sorin 
Group GmbH, Munchen, Germany). A roller pump with a non-pulsatile flow, about 2.5 litres / 
body surface area (m2) was used. Gas inflow to the oxygenator was adjusted using the alpha-stat 
method (Halstead et al. 2005). The temperature of venous blood was kept at 34°C. The arterial 
inflow was delivered through single cannulation of the ascending aorta or aortic arch. Venous 
drainage was through single venous cannulation inserted via the right atrial appendix in CABGs 
and aortic valve operations. Separate superior and inferior caval vein cannulations were utilized 
in mitral and tricuspid valve operations.  
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4.7. Myocardial protection (I, II, III, IV) 
 In Study I between the years 1991 and 1992, cardioplegia was performed with a 
modification of St. Thomas solution containing sodium 167 mmol/l, chloride 143 mmol/l, 
potassium 21 mmol/l, calcium gluconate 200 mg/l, magnesium 8 mmol/l, and nitroglycerin 2 
mg/l; at 4°C the pH was 8.1. Initially, the cardioplegic solution was infused into the aortic root 
until the heart stopped fibrillating and the target temperature (10°-15°C) was reached. 
Additional dose of cardioplegic solution was given into the aortic root after every 1-2 
anastomoses or at least every 20-30 minutes. The initial dose was usually less than 1000 ml, and 
subsequent doses were about 200-300 ml. No cardioplegic solution was given through the 
venous grafts. 
 Blood cardioplegia has been used in all valve and combined GABG-valve operations. Blood 
cardioplegia concentrate includes 400 ml of Ringer acetate, 100 ml of citrate-phosphate-
dextrose (CPD) solution (Baxter Ltd., IL, USA), 5 ml of Addex Tham buffer (Fresenius-Kabi 
AG, Uppsala, Sweden), 10 mekv of magnesium sulfate (MgSO4), and 50 mmol of potassium 
chloride (KCl). The temperature of blood cardioplegia was maintained before administration at 
12°C. The initial dose of cardioplegia was given with blood/concentrate ratio of 4:1, and 
subsequent doses with ratio of 8:1, respectively. In the valve operations, cardioplegia was 
delivered either antegradely through aortic root into the coronary ostia or retrogradely via the 
coronary sinus. 
 
4.8. Surgical procedures 
A summary of the surgical procedures and surgical details are shown in Table 7. 
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Table 7. Summary of indications, etiology and perioperative details of the Studies I, II, III, and IV. 
 
Characteristic Study I (n=180) Study II (n=184) Study III (n=104) Study IV (n=136) 
 
Indication for surgery 
 isolated CAD 180 (100) - 60 (58) - 
 CAD + AS and / or MR -  - 33 (32) - 
 ischemic MR -  114 (62) - - 
 degenerative MR -  64 (35) - - 
 rheumatic MR -  3 (2) - - 
 endocarditis -  3 (2) - 5 (4) 
 isolated TR -  - - 4 (3) 
 CAD + TR -  - - 3 (2) 
 ischemic MR + TR -  - - 18 (13) 
 degenerative MR + TR -  - - 61 (45) 
 rheumatic MR +TR -  - - 3 (2) 
 AS and / or MS -  - 11 (11) 27 (20) 
 ASD -  - - 9 (7) 
 VSD -  - - 1 (1) 
 congenital -  - - 1 (1) 
 myxoma -  - - 2 (1) 
 other -  - - 2 (1) 
Performed operations 
 CABG 180 (100) -  60 (58) -  
 MVP -  85 (46)  1 (1) - 
 MVR -  99 (54)  -  - 
 AVR -  -  9 (9) - 
 CABG + AVR and / or 
  MVR or MVP -  -  1 (1) - 
 MVP or MVR -  -  33 (32) - 
 TVP -  -  -  21 (15) 
 TVR -  -  -  4 (3) 
 TVP + AVR -  -  -  12 (9) 
 TVP + MVR -  -  -  43 (32) 
 TVP + MVP -  -  -  36 (26) 
 TVP + AVR + MVR -  -  -  14 (10) 
 TVP + AVR + MVP -  -  -  6 (4) 
Concomitant CABG 180 (100) 113 (61)  93 (89) 37 (27) 
Re-operation -  -  -  21 (15) 
Perfusion time (min) 150 ± 39 256 ± 58  151 ± 52 [63-333] 166 ± 67 [34-465] 
AO-time (min) 98 ± 31 134 ± 48  127 ± 45 [46-279] 134 ± 55 [29-295] 
Number of distal anastomoses  4.7 ± 1.4 2.5 ± 2.2  4.6 ± 1.5 [0-9] 0.76 ± 1.5 [0-6] 
Number of arterial grafts -  0.6 ± 0.5  -  0.14 ± 0.35 [0-1] 
Number of venous grafts -  1.9 ± 1.9  -  0.40 ± 0.76 [0-3] 
Amount of cardioplegia (ml) 1866 ± 743 -  -  2023 ± 897 
IABP -  -   - 16 (12)   
VAD -  -   - 1 (1) 
Perioperative MI 9 (5) -   4 (4) 22 (16)  
Stay in ICU (days) 2.6 ± 3.9  - 2.3 ± 2.9 [1-15] 2.9 ± 4.8 [1-35] 
Stay in hospital (days) 9.4 ± 5.5 - 8.4 ± 4.7 [2-30] 9.2 ± 6.2 [2-44] 
 
 
Values denote number of patients (percentages) or mean ± standard deviation [range]. AO-time = aortic occlusion time; 
AS = aortic stenosis; ASD = atrial septal defect; AVR = aortic valve replacement; CABG = coronary artery bypass 
grafting; CAD = coronary artery disease; IABP = intra-aortic balloon pump; ICU = intensive care unit; MI = myocardial 
infarction; MR = mitral regurgitation; MS = mitral stenosis; MVP = mitral valve plasty; MVR = mitral valve 
replacement; TR = tricuspid regurgitation; TVP = tricuspid valve plasty; TVR = tricuspid valve replacement; VAD = 
ventricular assist device; VSD = ventricular septal defect. 
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4.8.1. Coronary artery bypass grafting (I) 
 Between the years 1990 and 1991 CABGs were performed at the Kuopio University hospital 
as follows: anastomoses were performed with one or two sequential venous grafts and the use 
of at least one arterial graft. All vessels that had a stenosis of more than 50% of the lumen 
diameter at angiography and more than 1.5 mm in diameter were grafted. A membrane 
oxygenator was used, with bicaval cannulation by snaring of the cavae and venting of the left 
ventricle through the right upper pulmonary vein. General hypothermia of 25°-28°C was 
maintained during cardiac arrest. Rewarming was started at the beginning of the last distal 
anastomosis. Proximal anastomoses were performed with a sidebiting clamp after unclamping 
of the aorta. During that time only arterial grafts were open, and the heart usually started 
fibrillating. About 2-5 minutes after unclamping of the aorta, the first direct current (DC) shock 
of 8 to 10 J was given. The shock was repeated if fibrillation reappeared during the 
manipulation of the heart. Pacing wires were sutured to the myocardium of the right ventricle. 
The patient was weaned from the heart-lung machine when the rectal temperature was 34°C and 
the heart had received vented reperfusion through all the grafts for at least five minutes. Cardiac 
output and pressures were measured with a Swan-Ganz thermodilution catheter. The serum 
potassium concentrations were kept within the normal range in the operating room and in the 
intensive care unit. 
 
4.8.2. Mitral valve surgery (II) 
 During the study period, the technique of mitral valve surgery began to shift from MVR to 
MVP. Between the years 1992 and 1996 mitral valve procedures were performed at the Kuopio 
University hospital as follows: a perioperative transesophageal echocardiography was done after 
anesthesia induction, and the pathophysiology of the mitral valve was classified according to 
Carpentier’s nomenclature. A structurally normal mitral valve with normal leaflet motion but 
with annular dilation was Type I, increased leaflet motion indicating leaflet prolapse or flail was 
Type II, restricted leaflet motion in systole and diastole, usually associated with rheumatic 
leaflet and subvalvular thickening was Type IIIa, and restricted leaflet motion in systole, often 
seen in ischemic cardiomyopathy with history of myocardial infarction was Type IIIb. The 
grade of regurgitation was evaluated by mapping the spatial area of the color Doppler 
regurgitant jet and by measuring the regurgitant area or expressing the regurgitant area as a 
percentage of the left atrial size. In addition, pulmonary vein flow was recorded as regards 
blunting or systolic reversal of pulmonary vein flow during left ventricular systole and was 
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taken as an indicator of severity of mitral regurgitation. Using these two methods the severity of 
mitral regurgitation was graded as mild (1+), moderate (2+ to 3+), or severe (4+). 
Transesophageal echocardiography was repeated at the end of surgery and the surgical result 
was evaluated in the beating heart before decannulation of the aorta. 
 All mitral valve procedures were performed through a median sternotomy, and general 
hypothermia of 25°-28°C was maintained during the cardiac arrest. Arterial inflow was 
introduced via the ascending aorta and venous drainage was done through bicaval cannulation. 
Caval snares were used for inflow occlusion during the mitral valve exposure, and venting of 
the left ventricle through the apex of the heart was utilized. Cardioplegic solution was delivered 
both by the antegrade and the retrograde route. 
 The mitral valve apparatus was exposed either through interatrial Waterstons’s or 
Sondergaard’s groove or through the superior transseptal approach via the right atrium. The 
most common techniques to repair the mitral valve were quadrangular resection of the posterior 
leaflet with concomitant sliding plasty, annular plication, and triangular resection of the anterior 
leaflet. 
 All patients who underwent MVP received an annuloplasty ring. The most common device 
at that time was the rigid Carpentier-Edwards Classic® annuloplasty ring (Edwards Lifesciences 
Inc., CA, USA). 
 For patients undergoing MVR, Carbomedics® and Sorin Bicarbon® (Sorin Group Inc., CO, 
USA) were the most common prosthetic valves.  
 
4.8.3. Tricuspid valve surgery (IV) 
 In the case of severe TR due to a dilated tricuspid annulus, the technique of De Vega’s 
annuloplasty has been utilized until the end of the 1990’s. Since the beginning of the 
millennium, flexible annuloplasty rings have been used. The most common devices are the 
Tailor® (St. Jude Medical Inc., MN, USA) and Duran® (Medtronic Inc., MN, USA) 
annuloplasty rings. Recently, incomplete Carpentier-Edwards® annuloplasty bands (Edwards 
Lifesciences Inc., CA, USA) have been used instead of complete tricuspid annuloplasty rings to 
avoid conduction disturbances which may arise from the closed ring structure. 
 
4.9. ECG analysis, definition of CD, and indications and timing for PM (I, IV) 
 An immediate postoperative ECG was recorded soon after the patient had arrived in the 
intensive care unit, and thereafter ECGs were recorded every morning until the fifth 
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postoperative day and again at the day of discharge. Cardiac rhythm, atrioventricular 
conduction, intraventricular conduction, signs of myocardial infarction, and ST-segment and T-
wave change were recorded. CDs were classified into seven categories based on Satinsky et al. 
(1974) and the World Health Organization (Willems 1985) 1. first degree atrioventricular block 
(1st degree AV-block, PR interval >200 ms) 2. partial or complete left bundle-branch block 
(LBBB/CLBBB), 3. partial or complete right bundle-branch block (RBBB/CRBBB), 4. RBBB 
and left anterior hemiblock or left posterior hemiblock (RBBB/CRBBB + LAHB/LPHB), 5. 
LAHB or LPHB, 6. second degree atrioventricular block (2nd degree AV-block), and 7. third 
degree atrioventricular block (3rd degree AV-block). All ECGs were interpreted by an 
experienced cardiologist. The indications for PM were 1. persistent 2nd or 3rd degree AV-block, 
2. atrial fibrillation with a slow ventricular response, and 3. sinus node dysfunction. The 
decision to implant a PM and the timing of the implantation were always based on individual 
clinical judgment. The established policy at the Kuopio University Hospital is to wait until the 
fifth postoperative day before PM implantation in an attempt to allow time for transient 
conduction abnormalities to resolve. All PMs were implanted subcutaneously through the 
transvenous approach.  
 
4.10. The Nottingham Health Profile HRQoL analysis (II, III, IV) 
 The Nottingham Health Profile (NHP) is a generic measure of self-perceived health status 
(Hunt et al. 1981). It has been shown to be valid, reliable, easily completed, and acceptable to 
cardiac patients (Caine et al. 1999, Chocron et al. 2000, Herlitz et al. 2005). The NHP consists 
of 38 statements covering six dimensions of perceived health status. The dimensions are 
emotional reactions, pain, energy, social isolation, mobility, and sleep. In the NHP 
questionnaire, the statements are presented randomly and the respondent is asked to indicate 
whether or not the statement applies to him or her at present. Each statement has been weighted 
empirically to indicate their perceived severity, allowing scores to range from 0 to 100. The 
score obtained indicates the level of dysfunction or disability in the different domains. The 
higher the score, the greater is the perceived dysfunction. The NHP was selected for this study 
because it has been applied and validated previously to a random population sample to obtain 
standard values for the Finnish adult population. This standardization specifies the means and 
standard deviations of the different dimensions of the instrument relative to age and sex 
(Koivukangas et al. 1995). 
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4.11. Statistical analysis 
 Definitions, data analyses, and reporting were based on the guidelines and recommendations 
of the Joint Society of Thoracic Surgeons and the American Association for Thoracic Surgery 
Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity 
(II-IV; Edmunds et al. 1996, Akins et al. 2008). Data in the Tables are expressed as number of 
patients and percentage or mean and standard deviation (I-IV). Differences between groups 
were compared with the 2-test or Fisher’s exact test (I, II, IV) or Wilcoxon’s signed-rank test, 
marginal homogeneity test, and McNemar’s test (III). Continuous variables and proportions 
were compared with the non-parametric Mann-Whitney U-test or Student’s t-test after analysis 
of normality of distribution by the Kolmogorov-Smirnov test (I-IV). Late survival and time-
dependent events were depicted with Kaplan-Meier’s survival curves. The log-rank test was 
used for univariate analysis of mortality and morbidity followed by Cox’s multivariate analysis 
for statistically significant univariate factors (I-IV). Risk factors for impaired HRQoL and PM 
implantation were analyzed by binary logistic regression (II-IV). Differences with a p-value 
<0.05 were considered statistically significant. 
 Propensity score analysis was carried out in Study II to estimate the probability that a 
patient might undergo MVP or MVR and to eliminate the effect of non-randomization and 
selection bias. The theoretical basis of propensity score analysis has been published by 
Rosenbaum and Rubin (1983). Propensity scores are used to create matched pairs or matched 
sets that are balanced with respect to many observed covariates. The resulting matched sets are 
heterogeneous within the covariates, but the covariates aim to have uniform distributions in 
treated and control groups, which makes the groups as a whole comparable (Joffe and 
Rosenbaum 1999). As a result, logistic regression analysis of several preoperative variables was 
performed to generate a propensity score for each patient. In a subset analysis, patients were 
grouped according to the magnitude of their propensity score into quintiles, after which their 
characteristics and outcomes were compared within these quintiles. Groups with similar 
propensity scores were well matched with respect to all characteristics (II). Version 15.0 of the 
SPSS software was used to run the statistics (SPSS Inc., Chicago, Ill, USA). 
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5. RESULTS 
5.1. Postoperative CDs and long-term effects on survival after CABG (I) 
 Early mortality (within 30 days) was 1% (2/180). The causes of early deaths were cerebral 
infarct and septic shock. Survival after 9.6±0.2 years was 86% (155/180). 
 CDs at the time of discharge from the hospital were recorded in 63 patients (35%). Five 
patients (3%) received a PM due to permanent or intermittent 3rd degree AV-block. The 
prognostic factors for the development of a new CD after CABG were left main coronary artery 
diameter narrowing below 50% (p=0.02), perioperative myocardial infarction (determined as a 
new Q-wave in the ECG; p=0.04), postoperative CK-MB enzyme release (p=0.002), low 
cardiac output syndrome (determined as cardiac output below 2.0 l/min/m2; p=0.03), and 
prolonged postoperative care in a cardiac care unit (p=0.001). 
 Overall survival of the patients with a new CD (CD+ group) was significantly lower than in 
the CD- group (78% vs. 90%, p=0.02). Seven of the 14 deaths in the CD+ group (50%) and 
nine (82%) of the 11 deaths in the CD- group were of cardiac origin. Thus, cardiac mortality in 
the CD+ and CD- groups did not differ from each other (11% vs. 8%, p=NS). The overall 
mortality in the CD+ and CD- groups during the follow-up was lower than the predicted 
mortality of the age- and sex-matched reference population (18%). By multivariate analysis, 
five factors were significantly related to increased late mortality during the follow-up: diabetes, 
perfusion time, less than four distal anastomoses performed, a new CD, and an ejection fraction 
below 50% measured by preoperative transthoracal echocardiography. Detailed information on 
mortality predictors and risk ratios, 95% confidence intervals, and p-values are shown in Table 
8. 
 In the entire cohort, 7% underwent coronary angiography, 5% percutaneous coronary 
interventions, and 1% re-CABG during the long-term follow-up. 
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Table 8. Risk factors related to late mortality in Studies I, II, III, and IV. 
 
 RR  95 % CI p-value 
 
Perioperative need for hemofiltration (IV) 10.224 4.067-25.704 <0.0001 
Preoperative UAP (II) 4.359 2.159-8.799 <0.0001 
Diabetes (I) 5.990 2.430-14.780 <0.0001 
Perioperative MI (IV) 3.000  1.561-5.766 0.001 
Age >60 years (II) 1.070 1.027-1.115 0.001 
Preoperative severe renal failurea (IV) 4.797  1.696-13.571 0.003 
Use of mitral prosthesis (II) 2.713 1.391-5.289 0.003 
Perfusion  time (I) 1.020 1.010-1.030 0.003 
Number of distal anastomoses <4 (I) 3.200 1.300-7.880 0.010 
A new conduction defect (I) 2.830 1.240-6.490 0.010 
Urgency of the operation (III) 2.027 1.151-3.569 0.014 
Perioperative need for IABP (IV) 2.167  1.116-4.207 0.020 
Postoperative PM (IV) 0.289 0.104-0.806 0.020 
Ejection fraction <50% (III) 2.088 1.110-3.929 0.022 
Preoperative severe renal failureb (III) 2.054 1.047-4.026 0.036 
Ejection fraction <50% (I) 2.600 1.080-6.270 0.040 
Preoperative severe renal failureb (II) 1.004 1.000-1.007 0.050 
Preoperative cerebrovascular disorder (II) 2.713 0.985-5.289  0.054 
 
arenal failure (glomerular filtration rate <29 ml/min/1.73m2); brenal failure (creatinine level more than 105µmol/l); 95% 
CI = 95% confidence interval; IABP = intra-aortic balloon pump; MI = myocardial infarction; PM = permanent 
pacemaker; RR = risk ratio; UAP = unstable angina pectoris.  
 
 
 
5.2. Survival, morbidity and HRQoL differences between MVP and MVR (II) 
 CABG was simultaneously performed for 61 patients (72%) in the MVP group and 52 
patients (53%) in the MVR group. Early mortality (within 30 days) was 4% (8/184). The 5-year 
and actual survival was 81% and 74% in the MVP group, and 74% and 60% in the MVR group, 
respectively. After adjustment for baseline characteristics by the propensity score method, there 
was a statistically significant survival benefit for the patients who had undergone MVP when 
all-cause mortality was included (p=0.02; Figure 2). However, when only cardiac-related 
mortality was included, the acquired survival benefit from MVP was not statistically significant. 
Thirty-three patients (18%) died later than 30 days after the mitral valve procedure because of 
acute myocardial infarction. Sixteen patients (19%) died of acute myocardial infarction in the 
MVP group and 17 patients (17%) in the MVR group (p=1.00). Five of the deaths were 
categorized as valve-related deaths (3%) in the whole cohort. The death of one patient was 
categorized as valve-related in the MVP group (1%) and four deaths were categorized as valve-
related in the MVR group (4%; p=0.18). Among the 16 variables evaluated, five turned out to 
be statistically significantly associated with mortality. These were: preoperative unstable angina 
pectoris, age above 60 years, mitral valve prosthesis, preoperative renal failure, and 
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preoperative cerebrovascular disorder. Detailed information on the predictors of mortality and 
the risk ratios, 95% confidence intervals, and p-values are shown in Table 8. 
 
 
 
Figure 2. Propensity-matched Kaplan-Meier survival curves of patients who underwent either mitral valve 
plasty (MVP, n=85) or mitral valve replacement (MVR, n=99, II). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A non-fatal myocardial infarction occurred in six patients (7%) in the MVP group and in 
three patients (3%) in the MVR group during follow-up (p=0.21). Thromboembolic or bleeding 
events, i.e., stroke, transient ischemic attack, or intracerebral bleeding occurred in seven 
patients (8%) in the MVP group and in three patients (3%) in the MVR group (p=0.18). Re-
interventions (either coronary angiography alone or coronary angiography followed by 
percutaneous coronary interventions for ischemic symptoms) were done in two patients (2%) in 
the MVP group and in five patients (5%) in the MVR group, respectively, during the long-term 
follow-up. One patient (1%) underwent conversion from MVP to MVR later after primary 
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surgery. Three patients required a PM in the MVP group (4%) and two patients (2%) in the 
MVR group (p=0.83 for all interventions combined). 
 The HRQoL was studied on average 6.9 years after surgery in the MVP group and 8.2 years 
after surgery in the MVR group. There were no differences in the NHP-scores between the 
MVP and MVR groups in any of the six NHP-dimensions. However, the NHP-scores were 
statistically significantly higher in the study groups (MVP and MVR) than in the reference 
population concerning the dimensions describing energy (p=0.002 and p=0.004, respectively) 
and mobility (p=0.01 and p=0.03, respectively; Figure 3). Fourteen of the 37 tested variables 
had a statistically significant negative effect on HRQoL in the whole cohort. These contributors 
were mainly related to physical activity and physical performance (i.e., energy and mobility), 
but the dimensions describing pain and psychological dimensions, e.g., social isolation and 
emotion, were also affected by varying risk ratios. A summary of the statistically significant 
contributors to impaired HRQoL is shown in Table 9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Nottingham Health Profile (NHP) health-related quality of life scores and statistical differences 
between the mitral valve plasty (MVP) and mitral valve replacement (MVR) groups versus an age- and 
sex-matched reference population (II). *p=0.002; **p=0.004; ***p=0.01; ****p=0.03. 
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5.3. Cardiac surgery, survival and HRQoL of octogenarians (III) 
 Early mortality (within 30 days) was 4% (4/104). The causes of deaths were acute 
myocardial infarction for two patients (50%) and underlying valvular disease for two patients, 
as well 50%. 1-year, 5-year, and actual survival rates were 94%, 76%, and 59%, respectively. 
These did not differ from the predicted survival of the age- and sex-matched reference 
population (58%) after nine years (Figure 4). The actual survival of patients who had undergone 
CABG, valve surgery, or a combination procedure was 65%, 58%, and 47%, respectively 
(p=0.188). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Kaplan-Meier survival curves of 104 cardiac operated octogenarians versus age- and sex-
matched reference population during 8.2-years of follow-up (III). 
 
 
 There were 18 cardiac deaths (42%, 18/43) during the follow-up. Fifteen were categorized 
as ischemic (35%) and three as valve-related deaths (7%). Among the 17 variables that were 
evaluated, four turned out to be statistically significantly associated with mortality by univariate 
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analysis. Three were associated with increased mortality by multivariate analysis: urgency of 
the operation, preoperative ejection fraction below 50%, and preoperative renal failure. Detailed 
information on the predictors contributing to mortality together with the risk ratios, 95% 
confidence intervals, and p-values are shown in Table 8. 
 In terms of morbidity, non-fatal myocardial infarction occurred in four (9%) of the 
survivors. The cumulative number of thromboembolic or bleeding events, i.e., stroke, transient 
ischemic attack, or intra-cerebral bleeding, was 13 (28%). Coronary angiography due to 
ischemic symptoms but without re-interventions was done in one patient (1%). One patient 
(1%) had valve replacement 119 days after a previous mitral repair. Four patients required a PM 
(9%). 
 The HRQoL was studied 15±3.2 months and 8.2±0.27 years after surgery with the NHP-
questionnaire. The scores were compared with the scores standardized for the Finnish age- and 
sex-matched adult reference population at two time-points (65-74 years in 1993, and 75-80 
years in 2002). The score reflecting the experience of pain was statistically lower (p=0.001) in 
the study group than in the reference population 15 months after cardiac surgery, but eight years 
after surgery the study group did not differ from the reference population in terms of any of the 
HRQoL dimensions. Within the study group itself, however, the scores for energy (p=0.001), 
pain (p=0.003), and mobility (p=0.042) increased from 15 months to eight years after surgery. 
The NHP-scores in patients with CABG, valve surgery, or combination procedure groups 
differed from each other neither at 15 months nor at eight years of follow-up (Figure 5). 
 Six of the 40 tested presumptive variables turned out to be statistically significantly related 
to HRQoL (Table 9). Diabetes, a high energy score, and a high pain score at 15 months, 
treatment in an intensive care unit for more than three days, and a duration of cardiac symptoms 
before surgery for more than 120 days emerged as statistically significant predictors of impaired 
HRQoL in the dimensions describing energy, sleep, pain, emotion, and mobility. Patients using 
HMG-CoA-reductase inhibitors scored lower than the reference population in the dimension 
describing energy. 
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Figure 5. Nottingham Health Profile (NHP) health-related quality of life scores and 95% confidence 
intervals of the study group (Patients), and an age- and sex-matched reference population (Reference) at 
two different time-points in 1992 (92) and in 2002 (02, III). *p=0.001; **p=0.003; ***p=0.042. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4. PM therapy and survival, morbidity, and HRQoL after TV surgery (IV) 
 PM implantation was required by 28 of all reported 136 patients (21%) during follow-up 
(PM+ group). The mean time of implantation was 562±954 days [range, 5 to 3108 days] after 
surgery. Fifteen (54%) of the PMs were implanted already before hospital discharge. Fifty-two 
patients (39%) had needed temporary pacing immediately after the operation. Of these, 18 
(35%) received a PM either before hospital discharge or later during follow-up. Indications for 
PM were atrial fibrillation with slow ventricular rate in 16 (57%), sinus node dysfunction in 4 
(14%), and 3rd degree AV-block in eight (29%) patients. Among the tested variables, five 
emerged as statistically significant predictors or showed a marked trend for PM implantation:  
need for temporary pacing during the immediate postoperative period, female gender, lack of 
adequate cardiac rhythm on the first postoperative day, use of TV annuloplasty ring, and LBBB 
before the operation (Table 10). 
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Table 10. Risk factors for the need of PM after tricuspid valve surgery (Study IV). 
 
 
Variable RR  95% CI p-value 
 
Need for temporary pacing postoperatively 3.865  1.613-9.258 0.002 
Female sex 3.820  1.352-10.794 0.01 
No adequate cardiac rhythm at the 1st POD 2.387  1.160-4.915 0.02 
Use of annuloplasty ring vs. 
 other methods to repair TRa 2.732  1.072-6.965 0.04 
Preoperative LBBB 5.640  0.893-35.610 0.07 
 
   
95% CI = 95% confidence interval; LBBB = left bundle branch block; POD = postoperative day; RR = risk ratio; TR = 
tricuspid regurgitation. aOther methods include tricuspid valve replacement with prosthesis or De Vega annuloplasty.  
 
 
 Eleven patients (8%) died within 30 days after the operation. The causes of early deaths 
were valve-related in eight cases (73%), ischemic-related in two cases (18%), and respiratory 
insufficiency due to pulmonary fibrosis in one case (9%). All early deaths occurred in the PM- 
group. The 5-year, 10-year, and actual survival of the entire study population were 82%, 60%, 
and 63%, respectively (Figure 6). Survival in group PM+ was 100%, 94%, and 86%, and in 
group PM-  77%, 53%, and 57% respectively (p=0.01). Thus, after exclusion of the early deaths, 
the late survival figures in group PM- were 85%, 59%, and 64% (PM+ vs. PM-, p=0.05; Figure 
7). 
 Ten of the tested variables were significantly associated with mortality by univariate 
analysis: perioperative need of hemofiltration, perioperative MI determined as a new Q-wave in 
ECG or postoperative CK-MB enzyme release over 100 g/l, preoperative severe renal failure, 
need for a new PM, perioperative need for an IABP, preoperative MI, TR grade, unstable 
angina pectoris, stroke, and severe CAD. By multivariate analysis, five of the ten variables 
emerged as statistically significant predictors of late mortality. The multivariate model also 
showed that a new PM carried a protective effect against late death (Table 8).  
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Figure 6. Kaplan-Meier survival curve of 136 tricuspid valve operated patients versus an age- and sex-
matched reference population. Parallel gray lines indicate 95% confidence intervals for the reference 
population (IV). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In terms of late morbidity (>30 days after operation), non-fatal myocardial infarction 
occurred in one patient (4%) in group PM+ and in one patient in group PM- (2%, p=0.52). In 
terms of re-interventions, the number of patients who underwent coronary angiography due to 
ischemic symptoms or percutaneous coronary intervention during long-term follow-up was one 
(4%) in group PM+, and two (4%) in group PM- (p=0.21). Emergent CDs increased patient 
morbidity. The need for a PM prolonged hospitalization significantly (p=0.009). During the 
long-term follow-up, PM was significantly related to a higher incidence of thromboembolic 
complications in terms of transient ischemic attacks (PM+ vs. PM-; 30% vs. 6%, p=0.004) and 
strokes (PM+ vs. PM-; 9% vs. 4%, p=0.008). 
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Figure 7. Kaplan-Meier survival curves of 136 patients who needed a pacemaker (PM+) and those who 
did not (PM-) after tricuspid valve surgery. Early mortality (deaths within 30 days after the operation) is 
excluded (IV). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The HRQoL was studied cross-sectionally. Figure 8 shows the NHP scores of the study 
population by need of PM together with the scores standardized to the Finnish age- and sex-
matched reference population. Compared with the reference population, the entire patient 
population had significantly impaired mobility (p=0.007). The need for a PM was closely 
related to impaired HRQoL. Patients in group PM+ had significantly impaired HRQoL in the 
dimensions describing energy (p=0.01; p=0.04) and mobility (p=0.005; p=0.001) compared 
with group PM- and the reference population, respectively. Significantly more patients in group 
PM+ were in NYHA-class III and IV than in NYHA-class I and II compared to group PM- 
(p=0.03). On the other hand, group PM+ had a lower score for pain than the reference 
population (p=0.05). 
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Figure 8. Nottingham Health Profile (NHP) health-related quality of life scores and 95% confidence 
intervals for patients who required a pacemaker (PM+) compared with those who did not (PM-) need a 
permanent pacemaker after surgery (IV). *p<0.05; **p<0.01; ***p<0.001. 
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6. DISCUSSION 
6.1. Postoperative CDs and long-term effects on survival after CABG (I) 
 The effect of permanent CDs on prognosis after heart surgery has been controversial. Earlier 
reports have found that RBBB is the most frequent conduction abnormality after CABG and, at 
the same time, the most benign of all CDs. The incidence of left-sided blocks is lower, but they 
have been associated with an adverse outcome (Zeldis et al. 1978, Bateman at al. 1985). Current 
data also suggests that the type of CD after CABG has changed from the RBBB to 1st degree 
AV-block (Cook et al. 2005). Other have found no difference in prognosis of patients with or 
without CDs after CABG (Wexelman et al. 1986, Tuzcu et al. 1990), although there is some 
evidence that patients with a CD have poorer left ventricular systolic function and more often 
chest pain or dyspnea as the exercise-limiting symptom than patients without CDs (Mustonen et 
al. 1998). The largest of these studies included 2,000 patients 111 (6%) of whom developed a 
CD (Tuzcu et al. 1990). The 5-year overall survival was 86% in patients with and 87% in 
patients without CDs, and the cardiac survival rate was 95% in patients with and 93% in 
patients without CDs. Our results agree with these findings. The 5- and 10-year cardiac survival 
in our study was 95% and 92%, versus 92% and 89%, in group CD- and CD+, respectively. 
 Herlitz and co-workers reported 11 independent predictors of reduced survival during a 5-
year follow-up after isolated CABG (Herlitz et al. 1998): smoking, impairment of left 
ventricular function, a history of congestive heart failure, high age, arrhythmia 4-7 days after 
CABG, intermittent claudication, diabetes, prolonged ventilator time, history of cerebrovascular 
disease, treatment with digitalis at days 4-7 postoperatively, and cardiac enzyme release as a 
marker of myocardial injury. We found five independent predictors of all cause deaths: 
diabetes, perfusion time, number of distal anastomoses, permanent postoperative CDs, and 
preoperative left ventricular ejection fraction less than 50%. Four of these predictors have been 
documented previously by other authors (Herlitz et al. 1998, Myers et al. 1999). The effect of 
CDs on very long-term survival has not been reported previously. We found that not only 
rightsided, but also leftsided CDs are not related with inferior cardiac survival after CABG. 
However, 3rd degree AV-block emerged as a strong predictor of mortality. By multivariate 
analysis, 3rd degree AV-block was the only CD that was an independent risk factor for death. 
 The incidence of CDs in our study was relatively high (35%) and the spectrum wide but in 
line with clinical experience and results of some earlier studies (Caspi et al. 1987, Chu et al. 
1987, Caretta et al. 1991, Mustonen et al. 1995). One of three patients was discharged from the 
hospital with a new CD, but PMs were needed in less than 10% of them. The causes of post-
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CABG CDs seem to be multifactorial and some major contributors have been proposed. The 
main reason for the high incidence of CDs in our study was probably the myocardial 
preservation method used. A previously published analysis of the same patient cohort showed 
that in patients with a new permanent post-CABG CD, the perioperative myocardial 
temperature had been significantly lower than in patients with preserved conduction (Mustonen 
et al. 1995). It has been suggested that permanent damage of the conduction system after 
hypothermic myocardial protection is caused by temperature-induced changes in vital cellular 
functions of the conduction tissue during the post-ischemic period (Gozal et al. 1996). In our 
study, four of the studied variables remained significant predictors of permanent CDs by 
multivariate analysis: preoperative left main coronary artery stenosis, perioperative myocardial 
infarction determined as a new Q-wave in the ECG, postoperative CK-MB enzyme release, and 
prolonged stay in cardiac care unit. These contributors have been reported previously by other 
authors (Caspi et al. 1987, Chu et al. 1987, Caretta et al. 1991). The most recently published 
study corroborated these findings: Cook and colleagues found that the year of operation, age, 
use of intra-aortic balloon pump, number of vessels bypassed, and use of crystalloid 
cardioplegia were the most important predictors of emergent CDs after CABG (Cook et al. 
2005).  
 
6.2. Survival, morbidity and HRQoL differences between MVP and MVR (II) 
 The reconstructive techniques of mitral repair developed by Carpentier and colleagues have 
been suggested to be superior to mitral replacement in terms of survival (Braunberger et al. 
2001, Mohty et al. 2001, Suri et al. 2006). Moss and colleagues published the results of a 
population of 322 patients whom they had followed-up for 3.4 years (Moss et al. 2003). They 
concluded that MVP improved survival, but also that the number of re-operations increased. In 
our study of 184 patients with a mean follow-up of 7.3±1.4 years we found no significant 
differences in the rate of re-evaluations for surgery or re-operations between the MVP and MVR 
groups. Two authors have recently reported the results of lower mortality and morbidity after 
MVP compared to MVR, especially in late valve-related complications, e.g., thromboembolism 
and bleeding events (Lee et al. 1997, Yau et al. 2000). In Study II, we found no difference in the 
frequency of late complications between the MVP and MVR groups. 
 It has been clearly demonstrated that, in addition to the operative technique, underlying 
pathophysiologic mechanism of mitral valve disease contribute essentially to outcome (Cohn et 
al. 1995). The most common etiologies of mitral valve dysfunction are degenerative mitral valve 
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disease due to fibroelastic deficiency, Barlow’s disease, and mitral insufficiency due to ischemic 
cardiomyopathy (Filsoufi et al. 2005). Fibroelastic deficiency is common among elderly patients 
with a relatively short history of mitral regurgitation, whereas Barlow’s disease appears early in 
life, and patients typically have a long history of a systolic murmur. Ischemic mitral valve 
disease develops in parallel with CAD and causes mitral regurgitation by several mechanisms: 
typical clinical manifestations of ischemic mitral valve disease are annular dilatation, papillary 
muscle rupture, or leaflet prolapse due to fibrotic and elongated papillary muscles after 
myocardial infarction. In addition, myocardial infarction leads to left ventricular remodeling that 
changes the ventricular shape from ellipsoidal to spherical; such remodeling leads ultimately to 
papillary muscle displacement, reduced leaflet coaptation, and mitral regurgitation (Filsoufi et 
al. 2005). It is generally accepted that moderately severe to severe (grade 3+ or 4+) ischemic 
mitral regurgitation should be corrected at the time of CABG, but the optimal management of 
moderate (grade 2+) ischemic mitral regurgitation is still controversial (Raja et al. 2007). 
Srivastava and co-workers concluded in their review article that there is relatively good 
evidence that moderate mitral regurgitation in patients undergoing isolated CABG affects 
survival adversely and that mitral regurgitation does not with certainty improve after CABG 
alone. However, the evidence to support MVP or MVR at the time of CABG in the case of 
moderate or even mild mitral regurgitation to improve long-term survival is still weak 
(Srivastava et al. 2007). In this context, however, it is noteworthy to recall again that the results 
of MVP and MVR are essentially related to the underlying mitral valve pathology. In some 
cases, MVR may be the only feasible method to reconstruct mitral valve, e.g., in severe mitral 
stenosis or in mitral regurgitation, where MVP might be at first undertaken but then due to 
unsatisfactory outcome converted to MVR. In those cases where MVP is feasible, repair result 
has shown to be important predictor of the long-term outcome and recurrence rate. The 
immediate postoperative rate of residual regurgitation >1 predicts late failures requiring re-
operations (Heikkinen et al. 2005b).  
 The combination of mitral regurgitation and CAD is a growing challenge, where two 
separate but interdependent pathophysiologic mechanisms potentiate each other. An increasing 
number of patients with these coexisting diseases are offered the option to have cardiac surgery. 
Recently published data demonstrates that mitral insufficiency is an independent risk factor for 
reduced survival with CAD (Diodato et al. 2004, Grossi et al. 2006), but, unexpectedly, the 
selected technique to repair ischemic mitral regurgitation (MVP vs. MVR) does not contribute 
to the long-term outcome (Mantovani et al. 2004). Herlitz and co-workers studied 35 patients 
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who underwent both mitral valve surgery and CABG. They reported that the combination of 
valve surgery and CABG was independently associated with increased death rates and re-
hospitalizations. Early mortality was 11% and the 5-year survival 45%. The only independent 
predictor of an adverse outcome was a low ejection fraction (Herlitz et al. 1997). Mortality and 
survival figures were better in our Study (II): the early and 5-year survivals were 96% and 81%, 
respectively. In Study II, the survival difference between MVP and MVR groups was 
statistically significant only for all-cause mortality. In case of cardiac-only mortality, a long-
term survival difference did not emerge. Because life expectancy is affected by CAD and 
underlying poor ventricular function, patients with severe CAD have often reduced survival. 
One might argue that our results are preferentially CAD-related rather than valve-related, 
because patients with CABG were included. In our series, CABG was performed concomitantly 
with MVP for 72% of the patients and with MVR for 53%. The mean ejection fractions were 
54% and 63%, respectively. Thus, the patients in the MVP group presented with more severe 
CAD and worse left ventricular function than the patients in the MVR group. One would thus 
expect that the cardiac mortality in MVP group should be worse than in MVR group, but this 
was not a case (II). 
 In our study CABG done for unstable angina pectoris turned out to be an independent 
predictor of late mortality, whereas CABG for stable CAD was not significantly associated with 
mortality. Flameng and colleagues (Flameng et al. 1996) studied 741 patients who underwent a 
combination procedure (32 MVP and 180 MVR) and concluded that demographic variables, i.e., 
age (>70 years vs. 60>70 years vs. <60 years), female sex, renal failure, high NYHA-class III or 
IV, left ventricular dysfunction, amount of mitral regurgitation, CAD, non-sinus rhythm, and 
long aortic cross-clamp time were important predictors of early and late mortality in patients 
undergoing a mitral valve operation and CABG simultaneously. Our results agree very well 
with these findings, since we found that the following variables were associated with reduced 
survival: preoperative unstable angina pectoris, age older than 60 years, use of mitral prosthesis 
instead of valvular repair, preoperative renal failure, and preoperative cerebrovascular disorder. 
 Study II showed that HRQoL assessed with NHP was similar for patients who had 
undergone MVP or MVR. However, there was a statistical difference in the dimensions 
describing energy and mobility between the MVP and the MVR groups, on the one hand, and 
the standardized reference population on the other hand. No other HRQoL variable differed 
from the age- and sex-matched reference population. Two articles have reported that MVP 
might be superior to MVR as regards HRQoL (Goldsmith et al. 2001, Sedrakyan et al. 2006), 
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which stands in contrast to our study and the study by Immer and co-workers (Immer et al. 
2003). 
 In Study II we also assessed the determinants of impaired HRQoL of the patients who had 
undergone either MVP or MVR. Among the 37 tested variables, 14 were associated with an 
inferior HRQoL. The risk factors that affected more than three dimensions of the NHP did so 
mainly on physical dimensions (energy, mobility, and pain) and less on mental dimensions 
(sleep, social isolation, and emotion). The most significant variables associated with a poor 
HRQoL were high NYHA-class, age above 60 years, and need for nitroglycerin and diuretics. 
This is not unexpected, because these variables portray a symptomatic ischemic heart condition 
and heart failure, which are known to impair HRQoL. The relation between age and NYHA-
class with regard to impaired HRQoL has been reported previously (Chocron et al. 1996).    
 
6.3. Cardiac surgery, survival and HRQoL of octogenarians (III) 
 The patients’ own perception of their HRQoL is particularly important in older age: patients 
often value HRQoL above longevity. In Study III, the 1-year, 5-year, and actual survival rates 
of the patients who were operated at the age of 70 or older, were 94%, 76% and 59%, 
respectively. These survival rates are somewhat better than reported by Engoren and co-workers 
(Engoren et al. 2002) who studied 103 randomly selected septuagenarians undergoing cardiac 
surgery in 1998-1999, and reported 1-year and 2-year survival rates of all-patients of 83% and 
82%, respectively. In the CABG-only group, both the 1-year and the 2-year survival rates were 
90%. Survival in Study III is more in line with the results reported by Kolh and colleagues 
(Kolh et al. 2007). In their study of 220 octogenarians who were discharged from the hospital 
after aortic valve surgery (74%) with or without CABG (26%), the 1-year, 3-year, and 5-year 
survival rates for the entire study population were 86%, 80%, and 73%, respectively. Similarly 
to Kolh and associates, the actual survival rates in our study after combined valve- and CABG 
operations (47%) were lower than after isolated CABG (65%). 
 We sought to define risk factors that might predict death in the population who is operated at 
age 70 years or above. Multivariate analysis showed that risk factors for death were: urgency of 
operation, ejection fraction below 50%, and preoperative renal failure. Our results agree with 
previous findings (Kolh et al. 2007), which have shown that age, preoperative myocardial 
infarction, urgency of operation, and prolonged treatment in an intensive care unit were 
independently associated with high late mortality. The detrimental effect of preoperative renal 
failure on survival after cardiac surgery has been unambiguously reported earlier (Flameng et al. 
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1996, Melby et al. 2007). It is noteworthy that, in our series, the proportion of patients who had 
renal failure declined over time from 25% at baseline to 17% at 15 months and to only 4% at 8.2 
years. This underscores the importance of renal failure as a predictor of an extremely poor 
survival outcome. 
 The postoperative morbidity in Study III was not very high. Given that the patients were 
rather old, a rate of nonfatal myocardial infarctions of only 9% during follow-up was not very 
high. One patient underwent conversion to valve replacement after previous mitral repair, one 
patient underwent cardiac catheterization without further interventions, and four patients 
received a PM. The cumulative incidence of thromboembolic or bleeding events, i.e., stroke, 
transient ischemic attack, or intra-cerebral bleeding was 28% at 8.2 years, which is well in line 
with previous reports (Huber et al. 2007). 
 Three reports have addressed the question of the long-term effect of cardiac surgery on 
HRQoL in elderly patients (Järvinen et al. 2003, Huber et al. 2007, Loponen et al. 2007). During 
short-term follow-up, elderly patients have derived less HRQoL benefit from cardiac surgery 
than younger patients. Järvinen and co-workers (Järvinen et al. 2003) found, in a study of 508 
patients who had undergone CABG one year earlier, that patients aged >75 years had higher 
mortality and morbidity and also a poorer HRQoL compared to younger patients. Similar 
findings have been reported by Loponen and colleagues (Loponen et al. 2007): after initial 
improvement in HRQoL, the HRQoL of 56 patients who were older than 75 years at the time of 
CABG, returned to the preoperative level by 18 months after surgery. The study by Kolh and 
associates (Kolh et al. 2007) reported relatively good results in terms of HRQoL on average five 
years after aortic valve surgery, although the improvement in HRQoL was significantly 
associated with the preoperative status of the patients. A poor long-term HRQoL outcome may, 
in the elderly, be due to the natural progression of the underlying cardiac disease after surgery 
and to the co-morbidities related to old age. 
 In our study, cardiac operated septuagenarians at 15 months after surgery had less self-
reported pain than the age- and sex-matched reference population. Also, on average eight years 
after surgery, the study group did not differ from the reference population in terms of any 
HRQoL dimensions. The HRQoL of the patients decreased during eight years of follow-up in 
the dimensions describing energy, pain, and mobility, but that was the case in the reference 
population, as well. Thus, although cardiac operated septuagenarians coped as well as their age- 
and sex-matched controls, they did not present with better HRQoL in any specific dimensions at 
age of 80 years. At baseline, the cardiac operated patients are physically restricted by their 
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underlying cardiac disease. Our results imply that the efforts to relieve the symptoms related to 
the underlying cardiac disease by surgical means were successful. 
 Unexpectedly, the type of cardiac surgery did not contribute with any dimension of the 
HRQoL in our study: patients who had undergone CABG, valve surgery, or a combination of 
both all had similar HRQoL scores. However, it is known that the type of cardiac surgery is 
related to the postoperative perception of HRQoL. In a study by Falcoz, CABG-operated 
patients did not recover as well as patients who had undergone valve surgery (Falcoz et al. 
2003). In contrast, Huber and colleagues showed that octogenarians who had undergone either 
AVR or the combination procedure experienced more anxiety and worried more about dying 
than patients who had undergone isolated CABG (Huber et al. 2007). These mixed results 
reflect only too well the complexity related to the assessment of HRQoL.  
 We also studied the determinants of a poor HRQoL that affected the patients’ own 
perception of their HRQoL. Among 40 tested variables, five were associated with an inferior 
HRQoL: diabetes, high energy score at 15 months, high pain score at 15 months, treatment in an 
intensive care unit more than three days, and preoperative symptoms for more than 120 days 
were associated with poorer scores for energy, sleep, pain, emotion, and mobility after the long-
term follow-up. Patients on HMG-CoA-reductase inhibitors had a lower energy score. 
 The risk factors that had an impact on more than two dimensions of NHP influenced 
preferentially physical (i.e., energy and mobility) rather than mental domains. The most 
significant variables associated with impaired HRQoL in terms of physical conditions were 
diabetes and a high energy score at 15 months. In contrast to earlier studies (Falcoz et al. 2003, 
Peric et al. 2006), NYHA-class III and IV did not emerge as significant predictors of impaired 
HRQoL, although transition from NYHA-class I/II to class III/IV was statistically significant 
during the follow-up. However, the fact that this transition significantly increased the need for 
nitroglycerin during the follow-up supports the notion that the variables related to physical 
conditions are invariably more often affected than the mental dimensions, also among 
octogenarians. 
 In agreement with earlier reports (Kolh et al. 2007), diabetes with renal failure emerged as 
the most hazardous predictors for poor HRQoL outcome. Having diabetes predicted poor 
HRQoL as regards dimensions of energy, mobility, and pain. Regarding patient selection, a high 
energy score, and a high pain score at 15 months, and prolonged duration of symptoms 
preoperatively reflect the fact that decision-making whether to operate or not should be done 
without delay in order to achieve the optimum surgical results in terms of long-term HRQoL. 
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6.4. PM therapy and survival, morbidity, and HRQoL after TV surgery (IV) 
 The main finding in Study IV was that the need for a PM after TV surgery was high – 21% 
of the operated patients – and PMs were continuously needed during follow-up. Life expectancy 
among the PM-treated patients was higher than among the patients who did not need a PM. 
However, patients with a PM had a higher rate of thromboembolic complications and poorer 
HRQoL in terms of physical capacity than patients without a PM. 
 The incidence of PM after cardiac surgery is related to the type of operation. This is obvious 
for anatomical reasons. The early perioperative need for PM has been reported to be less than 
1% after CABG, and 3% to 6% after aortic valve and mitral valve or combination procedures 
(Morell et al. 1996, Gordon et al. 1998, Limongelli et al. 2003, Dawkins et al. 2008). However, 
the long-term need for a PM after cardiac surgery has not been thoroughly examined. The report 
of Onalan et al. (2008) seems to be the only one addressing the question of the need of PM after 
CABG or mitral and aortic valve surgery over time. They reported that 23% of the patients 
needed a PM during ten years follow-up. 
 The need and clinical implications of PM implantation after TV surgery is even less well 
documented. A limited number of studies imply that the need of PMs after TV surgery during 
the early perioperative phase is higher than after other valve surgery (13%-28%; Scully et al. 
1995, Do et al. 2000). More data regarding the general results and the need for PM after TV 
surgery are needed, because the current recommendations emphasize proactive and aggressive 
repair of secondary TR concomitantly with mitral surgery and revascularization. It has been 
predicted that the rate of TV surgery will increase along with the increasing rate of mitral repair 
and CABG (Tang et al. 2006). In Study IV we found that the incidence of PM after TV surgery 
is higher than after other valve surgery (Gordon et al. 1998, Koplan et al. 2003, Limongelli et al. 
2003). Although PMs were often implanted before the patient was discharged from the hospital, 
nearly half of them were implanted later. The mean time from surgery to PM implantation was 
562 days and the last PM in Study IV was implanted later than eight years after TV surgery. 
 Koplan et al. (2003) developed and validated a useful risk score to predict the need for PM 
after valve surgery. In their comprehensive series of 4,694 patients they found that preoperative 
RBBB or LBBB, multivalve surgery, especially when including TV surgery, preoperative PR-
interval >200 ms, prior valve surgery, and age >70 years were the strongest independent 
predictors for the need of PM. We found that the need for temporary postoperative pacing and 
the lack of adequate cardiac rhythm during the first postoperative day, as well as preoperative 
LBBB, and female sex were independent predictors of PM. An interesting finding in Study IV 
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was that the use of the annuloplasty ring rather than De Vega’s annuloplasty or prosthetic TV 
was an independent predictor of PM. De Vega’s annuloplasty was the standard procedure for 
TV repair at Kuopio University Hospital until the end of the 1990’s. In the beginning of the 
millennium, we used complete Tailor® (St. Jude Medical Inc., MN, USA) or Duran® (Medtronic 
Inc., MN, USA) flexible annuloplasty rings to repair the dilated tricuspid annulus if the patient 
had severe TR. Still more recently, we have used incomplete Carpentier-Edwards® annuloplasty 
bands (Edwards Lifesciences Inc., CA, USA) instead of complete tricuspid annuloplasty rings to 
avoid the development of conduction disturbances which may arise from to the closed ring 
structure. 
 The 5-year, 10-year, and actual survival was 82%, 60%, and 63%, respectively. In the report 
of Guenther et al. (2008) 416 patients underwent TV surgery; the 10-year survival was 48% in 
the TVP group and 37% in the TVR group. McCarthy et al. (2004) reported an 8-year survival 
of 50% among 790 patients who underwent TVP. Thus, the long-term survival in our study 
appears to be higher than in these studies. However, it is noteworthy that in our study most 
(95%) of the TV operations were repairs, whereas in the series of Guenther the proportion of 
repair was 75%. 
 The survival of patients who needed a PM after TV surgery was significantly higher than of 
those who did not. The survival rates at 5 years were 100% vs. 77%, and at 10 years 94% vs. 
53%. This marked survival difference remained significant after exclusion of early mortality in 
the group who never received a PM. The reasons for this difference are not clear, but one may 
speculate that PM patients are under more careful observation and – maybe more importantly – 
that the PM protected against fatal bradyarrhythmias. In our series there was only one death in 
the group of patients who received a PM that was categorized as cardiac-related (25%, 1/4 
patients), compared to 66% (33/50 patients) in the group who did not receive a PM. This 
hypothesis is difficult to verify, since bradyarrhythmias as the cause of death cannot be 
identified nor excluded postmortem by clinical examination or autopsy. However, risk factor 
analysis supported the hypothesis that PM improves survival, since the need for PM was 
ultimately the only protective factor against mortality during late follow-up. At the same time, 
we corroborated the findings of some previous studies (Gordon et al. 1998) on the impact of 
other risk factors on late mortality: preoperative or perioperative renal failure, perioperative MI, 
and perioperative need for IABP. This being the case the need for a PM as a protective factor 
against death gets some additional support.  
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 The need for a PM has been related to increased morbidity because the incidence of atrial 
fibrillation and cardiac failure increases. The development of PM-related cardiac morbidity is 
apparently related to the pacing site and to the duration of pacing (Sharma et al. 2005). 
Physiological pacing (AAI or DDDR) reduces the risk of cardiovascular end-points more than 
ventricular pacing (VVI; Tang et al. 2001, Nielsen et al. 2003). In Study IV, VVI was the most 
common pacing mode, which was related to the high prevalence of atrial fibrillation in this 
group of patients. Although PM patients had better survival, they also had an increased risk of 
thromboembolic complications and impaired HRQoL. The rates of transient ischemic attacks 
and strokes were significantly higher in the group of patients who received a PM than among 
those who did not. It is not clear why the rate of neurological events was higher among the 
patients who received a PM than among those who did not, since the higher rate of 
thromboembolic complications is not associated with the fact that a PM is placed in a patient’s 
right ventricle. 
 Data on HRQoL in the context of TV surgery is limited, but cardiac surgery is known to 
ameliorate HRQoL regardless of the type of underlying cardiac disease (Koch et al. 2007, Koch 
et al. 2008). In Study IV, the entire patient population coped similarly as the Finnish age- and 
sex-matched reference population, but the group of patients with a PM reported higher NHP-
scores in the dimensions describing energy and mobility. Another reflection of this increased 
morbidity in patients with PMs and impaired HRQoL was the fact that patients with a PM were, 
on average, more often of NYHA functional class III or IV compared to the patients who did not 
need a PM. It is noteworthy that disadvantageous outcomes, i.e., higher rates of neurological 
events, higher NYHA-classes, and impaired HRQoL, were not related to the rate of left-sided 
valve surgery, to the presence of atrial fibrillation, or to impaired left ventricular function. These 
circumstances support the assumption that PM implantation is related to increased morbidity 
and poor HRQoL.    
 
6.5. Integration of objective and subjective outcomes after cardiac surgery 
 Life expectancy has increased during the recent decades. The population of elderly citizens 
is growing in the Western world, including Finland. During the pioneer era of cardiac surgery in 
Finland in the mid-1950’s, life expectancy at birth for the overall population was approximately 
62 years (Tilastokeskus 2009b). Today, life expectancy has risen to 75.9 years for males and 
82.9 years for females (Tilastokeskus 2009b). By 2030, the proportion of persons aged over 65 
in the population is estimated to rise from the present 16% to 26%, and then to remain more or 
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less constant for the next decade. The proportion of persons aged over 85 in the population is 
predicted to rise from the current 1.8% to 6.1% by 2040. Thus, the number of people aged 80 
and above will rise from 94,000 today to 349,000 in 2040 (Tilastokeskus 2009c). Considering 
that heart diseases are the leading cause of death in the Western world and that the prevalence 
of heart diseases is steadily increasing, the amount of patients seeking treatment or referred for 
cardiac surgery will by necessity increase. This is also supported by the observation that despite 
maximal medical therapy many elderly patients remain severely symptomatic due to their 
cardiovascular disease, and they experience significant functional limitations.  
 Continuous advances in operative techniques, myocardial protection, and perioperative care 
have led to a steady decline in operative mortality. Cardiac surgery can be performed safely in 
patients aged 80 years and above, still with acceptable results (Fruitman et al. 1999, Kolh et al. 
2001, Engoren et al. 2002, Sedrakyan et al. 2003, Huber et al. 2007). Until very recently hard, 
objective variables like survival, mortality, morbidity, complication rate, symptom recurrence, 
and need for re-interventions were considered to be the only valid method to assess the outcome 
of patients undergoing cardiac surgery. Since the octogenarians and even older patients referred 
for cardiac surgery are approaching their maximum life expectancy, emphasis on survival alone 
in these patients following cardiac surgery may not be appropriate. Instead, patient selection 
criteria, comprehensive risk-factor analysis including outcome, HRQoL, and future hospital use 
may be the most important factors to influence surgical recommendations (Khan et al. 1998).  
The benchmark of cardiac surgical results should be a comprehensive integration of the both 
objective and subjective outcomes, or hard and soft endpoints. 
 In this study we showed that the life expectancy of patients who have undergone cardiac 
surgery, including septuagenarians, is comparable to the age- and sex-matched Finnish 
reference population. However, age over 60 years was an independent risk factor for mortality 
in patients undergoing mitral valve surgery (II). This observation is corroborated by other 
authors, as well (Brown et al. 2009, Maganti et al. 2009, Zingone et al. 2009). Not 
unexpectedly, survival outcome was closely related to the type of surgery. The 5-year survival 
rates in Studies II, III, and IV were 77%, 59%, and 82%, respectively, underlining the fact that 
older patients (III) do not survive as long as younger patients despite successful cardiac 
surgery. On the other hand, the survival difference between cohorts II and IV was small 
implying that tricuspid valve surgery in combination with CABG and/or aortic- and/or mitral 
valve surgery does not markedly reduce survival. In fact, the 5-year survival was longer in the 
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patients who had undergone concomitant tricuspid valve surgery (82%; IV) compared to those 
patients who had undergone only mitral valve surgery (77%, II). 
 In terms of risk factor analysis, renal failure and diabetes, either in combination or as 
separate entities, are the most important predictors of increased mortality after cardiac surgery. 
The importance of preoperative, perioperative, and postoperative renal failure and/or diabetes 
emerged as significant predictors of mortality in Studies I, III, and IV. This finding is well in 
line with previous studies (Flameng et al. 1996, Kolh et al. 2007, Melby et al. 2007). Cardiac 
interventions, if feasible, should be carried out before the underlying cardiac disease affects 
irreversibly cardiac and renal function. In Studies I and III, an ejection fraction below 50% 
emerged as a significant risk factor for mortality; this means that ischemic cardiomyopathy or 
cardiomyopathy due to other causes has proceeded to an irreversible state. The need for a PM 
after TV surgery emerged, unexpectedly, as a protective factor against mortality. The reason for 
this is not clear, but one may speculate that the PM patients after TV surgery were under more 
careful follow-up and – maybe more importantly – that the PM protected against fatal 
bradyarrhythmias. This hypothesis is difficult to verify since bradyarrhythmias as the cause of 
death cannot be identified or excluded by clinical examination or postmortem. However, risk 
factor analysis supported the hypothesis that PM improves survival, since the need for PM was 
ultimately the only protective factor against mortality during late follow-up. This finding is new 
and first published by our group (IV). 
 The HRQoL after cardiac surgery was comparable to the age- and sex-matched Finnish 
reference population in Studies II, III, and IV. However, several factors contributing to 
impaired postoperative HRQoL outcome could be adduced. There was more homogeneity 
within the factors related to physical capacity and exercise tolerance than to the factors related 
to mental conditions. It is also noteworthy that the risk profile of factors that were associated 
with impaired HRQoL varied significantly between Studies II and III. This is probably due to 
differences between patient demographics and operations performed: in Study II, patients were 
younger (62 years) and underwent primarily mitral valve-related procedures whereas in Study 
III, patients were markedly older (73 years) and underwent mainly CABG. However, age over 
60 years, higher pre- or postoperative NYHA-class, need for nitroglycerin or diuretics, and 
diabetes were the most important predictors of poor HRQoL after cardiac surgery in terms of 
physical dimensions (energy, pain and mobility). Higher NYHA-class and need for preceding 
medication affected also the mental dimensions (social isolation and emotion). Impaired 
physical capacity is likely to cause dejection in otherwise active cardiac patients. In general, 
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cardiac operated patients experienced less pain than the age- and sex-matched reference 
population. This observation has been made previously (Sjöland et al. 1997, Herlitz et al. 1999). 
Unexpectedly, the type of cardiac surgery did not contribute to any dimension of HRQoL (II, 
III, IV). Patients who had undergone either CABG, valve surgery, or a combination procedure 
performed similarly on both physical and mental HRQoL scores.   
 
6.6. Study limitations 
 From a methodological perspective, an obvious limitation of this study is the lack of 
randomization. However, it is very difficult to design prospective randomized clinical trials that 
compare only, e.g., the effect of the type of cardiac surgery in terms of outcome (Blackstone 
2001 and 2002). The obvious reasons are that such studies carry great heterogeneity of patients 
and for ethical reasons the operative techniques cannot be selected randomly. Thus, treatment is 
confounded by selection bias, and any observed outcome differences could relate to a number of 
concealed underlying causes. In this study, we attempted to adjust for selection factors by using 
multivariate analysis, by investigating objective outcomes by logistic regression, and by 
stabilizing unavoidable patient heterogeneity by propensity score matching (II). Another 
limitation of this study is the cross-sectional composition of the HRQoL analysis in Studies II 
and IV, and the lack of preoperative HRQoL assessment. Data on HRQoL were not routinely 
collected in the 1990’s, and thus we were not able to assess the change in the HRQoL 
longitudinally over time, except in Study II. We were, however, able to compare the HRQoL of 
the cardiac operated patients with an age- and sex-matched Finnish reference population. So far, 
there are not any approved methods to standardize subjective outcomes, such as HRQoL. 
 The single-center nature and the obligatory loss of patients inherent to long-term follow-up 
studies are also potential methodological restriction of this study. The loss of only 25% of 
elderly patients during eight years follow-up (III) is, on the other hand, quite small and does not 
invalidate the major results. From the HRQoL perspective, it is impossible to standardize all 
demographic characteristics of all patients in terms of education, profession, social status, and 
cultural background. 
 In Study I, the last ECG recording was performed on the day of discharge, and no additional 
recordings were routinely done. Thus, some of the CDs might still have resolved after discharge 
from hospital. Although Study I shed light on the survival of CABG patients compared with the 
age- and sex-matched Finnish reference population, the study does not present any direct 
74 
 
  
information on the survival of CABG patients in comparison with similar patients who were not 
treated in the same way. 
 In Study IV, patients who underwent TV surgery were a very heterogeneous group. 
Tricuspid valve regurgitation is nearly always secondary to mitral or aortic valve pathology or 
CAD, and mitral and/or aortic valve surgery or CABG is often performed concomitantly with 
tricuspid repair. Many of the patients had also undergone cardiac surgery previously. Thus, one 
has to be careful when applying these results to isolated TV surgery. 
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7. CONCLUSIONS 
In this study, we reviewed comprehensively both objective and subjective outcome variables of 
patients who were referred for cardiac surgery. We addressed several clinically relevant risk 
factors contributing to impaired outcome and made the following specific observations:  
  
1. Survival of CABG patients is comparable to an age- and sex-matched reference 
population. CABG-related permanent CDs are associated with prolonged hospitalization, 
but CABG-related CDs do not contribute to increased cardiac mortality during long-term 
(9.6±0.2 years) follow-up. 
 
2. Survival is longer after MVP than after MVR. The HRQoL of MVP and MVR patients is 
similar. In terms of the variables related to HRQoL, mitral valve operated patients do not 
differ markedly from the age- and sex-matched reference population.  
 
3. The long-term HRQoL and survival of octogenarians who have undergone cardiac surgery 
at the age of 70 years is comparable to the HRQoL and survival of the age- and sex-
matched reference population. The HRQoL of octogenarians deteriorates over the years 
after cardiac surgery especially of the physical domains. 
 
4. The need for a new PM after TV surgery is high – and PMs are continuously needed 
during long-term follow-up. Still, life expectancy among PM-treated patients is longer 
than among the patients who did not need a PM after TV surgery. Although PM treatment 
improves survival, the patients who have a PM implanted have an increased risk of 
thromboembolic complications and impaired HRQoL in terms of physical domains. 
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8. YHTEENVETO (FINNISH SUMMARY) 
 Sydänkirurgian tuloksia on perinteisesti arvioitu objektiivisilla mittareilla kuten 
sydänleikkaukseen liittyvällä kuolleisuudella, vertaamalla sydänleikkauspotilaiden 
elinaikaennustetta ikä- ja sukupuolivakioituun normaaliväestöön, sydänleikkaukseen liittyvien 
komplikaatioiden laadulla ja määrällä sekä uusintaoperaatioiden tarpeella. Vaikka 
objektiivisesti mitattavat suureet ovat keskenään vertailukelpoisia, ne eivät kerro mitään 
sydänkirurgialla saavutettavasta subjektiivisesta hyödystä potilaalle. Sydänleikkauksella 
saavutettava subjektiivinen hyöty voidaan arvioida sydänleikkauksen jälkeisenä parantuneena 
elämänlaatuna. Sydänleikkauksen vaikutus elämänlaatuun tulee tulevina vuosina entisestään 
korostumaan, koska sydänleikkaus on mahdollista tehdä entistä pienemmällä riskillä yhä 
iäkkäämmille ja aikaisempaa huonokuntoisemmille potilaille. Erityisesti iäkkäiden potilaiden 
kohdalla sydänkirurgian merkitys subjektiivisesti koettuun elämänlaatuun korostuu, kun taas 
objektiivisesti saavutettavan hyödyn, kuten elinaikaennusteen, merkitys vähenee. Toisaalta 
myös rajallisten terveydenhuollon resurssien vuoksi on perusteltua, että tehdyillä 
hoitotoimenpiteillä on todellinen potilasta hyödyttävä vaikutus. Terveyteen liittyvän 
elämänlaadun mittaamisesta on tullut keskeinen väline sydänkirurgisten hoitotulosten 
arvioinnissa ja potilaan kokemusta sydänleikkauksen vaikutuksesta elämänlaatuun on pidettävä 
nykyään vähintään yhtä tärkeänä hoidon onnistumisen mittarina kuin pidentynyttä 
elinaikaennustetta. 
 Väitöskirjatyössä selvitettiin sydänkirurgisen hoidon vaikuttavuutta tutkimalla Kuopion 
yliopistollisessa sairaalassa vuosien 1990–2007 välisenä aikana sydänleikattujen potilaiden 
elinaikaennustetta, sydänleikkauksen jälkeistä sairastavuutta, uusintaoperaatioiden tarvetta, 
elämänlaatua ja edellä mainittuihin vaikuttavia riskitekijöitä. Väitöskirjatyö koostui neljästä 
osatyöstä. Ensimmäisessä ja neljännessä osatyössä tarkasteltiin erityisesti sydänkirurgiaan 
liittyvien johtumishäiriöiden vaikutusta elinaikaennusteeseen ja elämänlaatuun. Tutkimus-
aineistona oli 604 potilaasta, joiden tiedot saatiin kirurgian ja anestesiologian klinikoiden 
yhteisestä prospektiivisesti kertyvästä sydänleikkausrekisteristä. Potilaiden seurantatiedot 
kerättiin poliklinikkakäyntien yhteydessä, Tilastokeskuksen ylläpitämästä kuolemansyy-
rekisteristä ja potilaille lähetetyillä kyselylomakkeilla. 
 Ensimmäisessä osatyössä selvitettiin 180 peräkkäisen elektiivisesti leikatun ohitusleikkaus-
potilaan elinaikaennustetta ja leikkauksessa syntyneen pysyvän johtumishäiriön vaikutusta 
elinaikaennusteeseen. Elektiivisesti ohitusleikattujen potilaiden elinaikaennuste oli yhtä hyvä 
kuin ikä- ja sukupuolivakioidun verrokkiväestön elinaikaennuste. Kuolemanriskiä lisääviä 
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tekijöitä kaikki kuolemansyyt huomioivassa monimuuttujamallissa olivat ohitusleikkauksen 
yhteydessä syntynyt pysyvä johtumishäiriö, diabetes, perfuusioaika, ohitusten lukumäärä ja 
heikentynyt vasemman kammion funktio. Pysyvä johtumishäiriö ei kuitenkaan lisännyt 
sydänperäisten kuolemien määrää. 
 Toisessa osatyössä verrattiin mitraaliplastia- (n=85) ja mitraalitekoläppäleikkauksen (n=99) 
vaikutuksia potilaiden elinaikaennusteeseen ja elämänlaatuun. Vertailu tehtiin vakioimalla 
potilaat leikkausta edeltävien muuttujien suhteen propensity score -menetelmällä. 
Mitraaliplastiapotilaiden elinaikaennuste oli tilastollisesti merkitsevästi parempi kuin 
mitraalitekoläppäpotilaiden, ja mitraalitekoläpän käyttö osoittautui itsenäiseksi kuolemanriskiä 
lisääväksi tekijäksi monimuuttujamallissa. Muita kuolemanriskiä lisääviä tekijöitä olivat 
leikkausta edeltävä epästabiili angina pectoris -oire, yli 60 vuoden ikä, leikkausta edeltänyt 
munuaisten vajaatoiminta ja iskeeminen aivotapahtuma. Valitulla leikkaustekniikalla 
(mitraaliplastia vs. mitraaliproteesi) ei ollut vaikutusta potilaiden subjektiivisesti kokemaan 
leikkauksen jälkeiseen elämänlaatuun. Mitraaliläppäleikattujen potilaiden elämänlaatu vastasi 
ikä- ja sukupuolivakioidun verrokkiväestön elämänlaatua lukuun ottamatta fyysistä 
suorituskykyä kuvaavia Nottingham Health Profile -elämänlaatumittarin ”tarmokkuus” ja 
”liikkuminen” ulottuvuuksia. Tutkimuksessa löydettiin 14 muuttujaa, jotka osoittautuivat 
mitraaliläppäleikkauksen jälkeistä elämänlaatu heikentäviksi itsenäisiksi riskitekijöiksi. 
 Kolmannessa osatyössä selvitettiin 104:n yli 70 vuoden ikäisenä sydänleikatun potilaan 
elinaikaennustetta, ennusteeseen vaikuttavia tekijöitä ja elämänlaatua keskimäärin 15 
kuukauden ja 8 vuoden jälkeen leikkauksesta sekä elämänlaatuun vaikuttavia tekijöitä. Yli 70-
vuotiaana sydänleikattujen potilaiden elinaikaennuste oli vastaava kuin ikä- ja 
sukupuolivakioidun verrokkiväestön. Itsenäisiä kuolemanriskiä lisääviä tekijöitä olivat 
leikkauksen kiireellisyys, heikentynyt vasemman kammion funktio, leikkausta edeltänyt 
munuaisten vajaatoiminta ja pitkittynyt leikkauksen jälkeinen tehohoitojakso. Potilaiden 
subjektiivisesti kokema elämänlaatu vastasi ikä- ja sukupuolivakioidun verrokkiväestön 
elämänlaatua 15 kuukauden ja 8 vuoden seurannassa lukuun ottamatta kipua kuvaavaa 
ulottuvuutta: 15 kuukauden kohdalla sydänleikatut potilaat kokivat vähemmän elämänlaatua 
haittaavaa kipuoiretta kuin verrokkiväestö. Kuitenkin 8 vuoden seurannan aikana 
sydänleikattujen potilaiden subjektiivisesti kokema elämänlaatu heikkeni samalla tavalla kuin 
verrokkiväestönkin ”tarmokkuutta”, ”kipua” ja ”liikkumista” kuvaavissa ulottuvuuksissa. 
Tutkimuksessa löydettiin 7 muuttujaa, jotka osoittautuivat sydänleikkauksen jälkeistä 
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elämänlaatua heikentäviksi itsenäisiksi riskitekijöiksi yhdessä tai useammassa elämänlaatua 
kuvaavassa ulottuvuudessa. 
 Neljännessä osatyössä tutkittiin 136:n trikuspidaaliläppäleikatun potilaan leikkauksen 
jälkeistä pysyvän tahdistimen tarvetta, elinaikaennustetta, elämänlaatua ja näihin vaikuttajia 
tekijöitä. Välittömästi trikuspidaaliläppäleikkauksen jälkeen tai keskimäärin 8 vuoden seuranta-
aikana pysyvän tahdistimen tarvitsi johtumishäiriön vuoksi 21 % potilaista. Määrä on 
poikkeuksellisen suuri yleisesti sydänkirurgiaan liittyvän pysyvän tahdistimen tarpeeseen 
verrattuna. Pysyvällä tahdistimella oli yllättäen elinaikaennustetta parantava vaikutus, sillä se 
oletettavasti suojasi potilaita rytmi- tai johtumishäiriöperäiseltä äkkikuolemalta. Pysyvän 
tahdistimen tarve lisäsi kuitenkin tromboembolisten komplikaatioiden ilmaantuvuutta ja 
heikensi potilaiden elämänlaatua erityisesti fyysistä suorituskykyä kuvaavissa ulottuvuuksissa. 
Trikuspidaaliläppäleikattujen potilaiden elinaikaennuste oli yhtä hyvä kuin ikä- ja 
sukupuolivakioidun verrokkiväestön. Itsenäisiä kuoleman riskiä lisääviä tekijöitä olivat välitön 
leikkauksen jälkeinen dialyysiä vaatinut munuaisten vajaatoiminta, leikkauksen aikainen 
sydäninfarkti, leikkausta edeltänyt munuaisten vajaatoiminta ja leikkauksen jälkeinen 
kontrapulsaattorin tarve. 
 Väitöskirjatutkimuksesta saatu tieto auttaa suuntaamaan potilasvalintaa siten, että 
sydänkirurgisen hoidon piiriin valikoituvat potilaat, jotka sekä objektiivisilla että subjektiivisilla 
mittareilla arvioituna sydänleikkauksesta oletettavasti eniten hyötyvät. Toisaalta tutkimus auttaa 
tunnistamaan riskipotilaat, joiden leikkaukseen, leikkauksen jälkeiseen toipumiseen ja 
leikkauksen jälkeiseen elämänlaatuun liittyy todennäköisesti ongelmia. Vaikka pysyvä tahdistin 
saattaa suojata potilaita johtumishäiriöperäiseltä kuolemalta, se heikentää elämänlaatua 
erityisesti fyysistä suorituskykyä kuvaavissa ulottuvuuksissa.   
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NHP - TERVEYSPROFIILI 
 
 
 
 
 
Miten kuvaisitte tämänhetkistä terveydentilaanne ? 
 
 
 Erittäin hyvä  
 Hyvä  
 Melko hyvä  
 Huono  
 Erittäin huono  
 
 
 
 Päivämäärä_____________ 
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OSA I 
 
Alla on lueteltu joitakin vaivoja, joita ihmisillä voi olla päivittäisessä elämässään. Käykää 
luettelo läpi ja merkitkää rasti KYLLÄ -ruutuun kaikkien niiden vaivojen kohdalle, joita teillä 
tällä hetkellä on. Merkitkää rasti EI -ruutuun aina kun teillä ei ole kyseistä vaivaa. 
Olkaa hyvä ja vastatkaa jokaiseen kysymykseen. Mikäli olette epävarma siitä, onko vas-
tauksenne kyllä vai ei, merkitkää se vaihtoehto, joka mielestänne on tällä hetkellä totuuden-
mukaisempi. 
 
 
   
 KYLLÄ EI 
Olen koko ajan väsynyt   
Minulla on kipuja öisin         
 
        KYLLÄ  EI 
Käytän lääkkeitä päästäkseni uneen       
 
        KYLLÄ  EI 
Asiat masentavat minua         
Asennon vaihtaminen on minulle tuskallista      
Hermoni ovat kireällä         
 
        KYLLÄ  EI 
Tunnen itseni yksinäiseksi         
Pystyn kävelemään vain sisätiloissa       
Minulla on sietämättömiä kipuja        
 
        KYLLÄ  EI 
Minun on vaikea kumartua         
Kaikki asiat vaativat ponnistelua        
 
        KYLLÄ  EI 
En pysty lainkaan kävelemään        
Herään hyvin aikaisin aamulla        
Olen unohtanut, millaista on nauttia elämästä      
 
        KYLLÄ  EI 
Minun on vaikea lähestyä ihmisiä        
Minulla on kipuja kävellessä        
Päivät tuntuvat matelevan         
 
        KYLLÄ  EI 
Minun on vaikea nousta ja laskeutua portaita      
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Jos olette epävarma siitä, onko vastauksenne kyllä vai ei, merkitkää se vaihtoehto, joka 
mielestänne on tällä hetkellä totuudenmukaisempi. 
 
 
   
    
 KYLLÄ EI 
Minun on vaikea kurottaa esineitä        
Menetän nykyään malttini herkästi        
 
        KYLLÄ  EI 
Makaan valveilla suurimman osan yötä       
Tuntuu kuin olisin menettämässä hallintani      
Minulla on kipuja seistessä         
 
        KYLLÄ  EI 
Minusta tuntuu, että en ole läheinen kenellekään      
Minun on vaikea pukea itseäni        
 
        KYLLÄ  EI 
Voimani loppuvat nopeasti         
Minun on vaikea seistä pitkään        
Minulla on jatkuvia kipuja         
 
        KYLLÄ  EI 
Minun on vaikea päästä uneen        
Minusta tuntuu, että olen vaivaksi ihmisille      
 
        KYLLÄ  EI 
Huolet pitävät minut valveilla öisin       
Tuntuu, että elämä ei ole elämisen arvoista      
 
        KYLLÄ  EI 
Nukun huonosti öisin         
Tarvitsen apua kävellessäni ulkona        
 
        KYLLÄ  EI 
Tunnen kipua kulkiessani ylös ja alas portaita      
Herään masentuneena         
 
        KYLLÄ  EI 
Minun on vaikea tulla toimeen ihmisten kanssa      
Tunnen kipua istuessani         
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